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ABSTRACT
Clinical trials are an essential part of the drug development life cycle. There are different
types of clinical trials, and in this dissertation, we focus on non-inferiority (NI) trials. In
NI trials the goal is to show that the effectiveness of a new treatment is not considerably
worse than of a standard one by an acceptable margin. Although, the new treatment
could be slightly less efficacious, it can offer other benefits such as less severe adverse
reactions.
Several methodological challenges have been reported regarding the design, analysis
and interpretation of NI trials. These include incomplete data analysis, specification of
an acceptable margin, and overall benefit of the new non-inferior treatment. Therefore,
the aim of this dissertation was to address each of these challenges and provide practical
solutions for researchers involved with NI trials.
First, we focus on incomplete data. Specifically, we evaluate how different statistical
strategies perform under several NI scenarios and various types of missingness. We pro-
vide a set of recommendations for practitioners to use when confronted with incomplete
Yulia Sidi, University of Connecticut, 2020
data to avoid false non-inferiority conclusions. Second, while performing a thorough
investigation of proper statistical strategies for incomplete data analysis, we discovered
that combination rules of multiply imputed data when inference is done using a New-
combe’s method did not exist. As a result, we developed these combination rules. Third,
we proposed a new framework that allows for a transparent and objective justification
of an acceptable margin. The framework is based on combining results of NI study and
clinical experts survey data using multiple imputation (MI). Fourth, we developed a new
approach for a comprehensive benefit-risk assessment of a non-inferior treatment. We
focus on preference elicitation regarding benefits and risks from a small sample of NI
trial participants, and use MI to restore preferences of all study participants.
This dissertation provides an important contribution to the field of Statistics, and
drug development. The novel methods and techniques outlined in this dissertation fa-
cilitate practitioners involved with NI trails to make more efficient and transparent
evaluations of treatment effectiveness.
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1Chapter 1
Introduction
1.1 Non-inferiority trials background
Non-inferiority (NI) clinical trials seek to demonstrate that efficacy of a new treatment is
not considerably worse than that of a standard treatment [FDA, 2016]. Such minimally
acceptable deviation is called margin. The margin is determined using historical data
for the standard treatment effect over placebo, and clinical expert opinions regarding the
clinically acceptable reduction of that effect. While a portion of a standard treatment
effect may be lost by a non-inferior agent, it offers other benefits, such as less severe ad-
verse events, improved drug adherence and/or lower costs [Piaggio et al., 2012]. NI trial
design is usually considered when the use of placebo is unethical, as delaying treatment
with standard care would cause irreversible health damage or death [ICH, 2000, FDA,
2016].
In the past, NI trials were relatively rare, however, the number of clinical trials using
this design increased significantly over time. Suda et al. [2011] evaluated 583 NI trials
published between 1989 and 2009, and reported a steadily increasing publication rates.
Murthy et al. [2012] perfomed a similar evaluation between 1999 and 2010, which led to
2a similar conclusion. Moreover, we searched PubMed in Oct-2019, and found that the
number of clinical articles mentioning non-inferiority in title or abstract was 296 in 2010
and reached 713 in 2017 (Figure 1).
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Figure 1: Number of published non-inferiority clinical trials
There are two different approaches to analysis of NI trials: fixed margin method
and synthesis method [Rothmann et al., 2016, FDA, 2016]. Both approaches rely on
historical data and the opinions of clinical experts, but in a different way. The fixed
margin method could be seen as a two step approach. At the first step, one needs
to determine the standard treatment effect over placebo (M1), which is usually done
through a meta-analysis of historical data. Then, a clinically acceptable margin (M2),
which has to be strictly lower than M1 is chosen by clinical experts. The comparison
between a standard and a new treatment from an NI trial is done with respect to the
pre-defined margin M2, as if it was a fixed constant. In the synthesis method, the
3historical data are “combined” with the NI trial data, so that the new treatment is
compared to putative placebo using a clinically acceptable threshold. A recent FDA
guideline for NI trials recommends using fixed margin over synthesis method [FDA,
2016]: “Notwithstanding that the interpretation of an NI study is fundamentally a
synthesis, we recommend a statistical method, the fixed-margin method, that treats the
problem in two separate steps.” Following FDA’s recommendation, the fixed margin
approach was used throughout this dissertation along with a “commonly used” method
of 95%-95% confidence interval (CI) [FDA, 2016]. The first 95% CI refers to the standard
treatment effect over placebo from historical studies, while the second 95% CI compares
the standard and new treatments in the current NI study. To determine NI of the new
treatment, the the lower/upper bound of the later CI is compared to M2.
Recent review articles of published NI trials reveal that a substantial improvement is
required for design, analysis and reporting of NI trials [Rehal et al., 2016, Aberegg et al.,
2017, Rabe et al., 2018]. Incomplete data analysis, as well as margin justification, were
among the issues discussed in these reviews. Moreover, several other authors indicated
that there is a need for proper assessment of the overall advantages of a non-inferior
treatment over a standard treatment [Garattini et al., 2003, Gladstone and Vach, 2015,
Evans and Follmann, 2016]. Following that, we have devoted this dissertation to these
topics, with the goal of improving current practices for design and analysis of NI trials.
41.2 Incomplete data analysis in NI trials - current
practices
Like most clinical trials, NI trials are prone having incomplete data, which if not properly
analyzed might lead to bias results [Little and Rubin, 2014]. The importance of avoiding
missing data, and performing appropriate analysis of incomplete data in clinical trials
has been extensively discussed [Fleming, 2011, CMPH, 2010, NRC, 2011, Little et al.,
2012, Dziura et al., 2013]. However, missing data has received little attention in NI
trials. Wiens and Zhao [2007] describe missing data as one of “the biggest obstacles
to interpretation of NI studies” and state that more work on this topic is required.
Fleming [2008] briefly mentions missing data as a possible source for biased results which
might lead to apparent similarities between treatments. Gallo and Chuang-Steiny [2009]
provide some considerations in regards to analysis of incomplete data in NI studies.
A common framework for missing data is based on the following missingness mecha-
nisms: missing completely at random (MCAR), missing at random (MAR), and missing
not at random (MNAR) [Rubin, 1976, Little and Rubin, 2014]. MCAR essentially means
that the missing values in the study are completely independent of the data observed
or not observed in the study. MAR implies that missing values depend on observed
data. MNAR means that missing values depend on unobserved data. MCAR is un-
likely to hold in clinical trials [NRC, 2011], therefore, analysis based on this assumption
should be avoided, unless it is imposed by design (for example, randomly sampling trial
5participants for an ancillary study) [Graham et al., 2006, Little and Rhemtulla, 2013].
In addition to the missingness mechanism, distinctness between data model parameters
and parameter involved in generation of missing values plays a central role in incomplete
data analysis. For likelihood and Bayesian based inferences, ignorability is characterized
by both MAR and distinctness between the parameters mentioned above. As a result,
non-ignorability holds when at least one of these two assumptions is violated. For sim-
plicity, we will use MAR/ignorabile and MNAR/non-ignorabile terms interchangeably
throughout this dissertation.
Previously, only a handful of simulation studies have been conducted to assess the
impact of different analysis strategies on NI trials [Yoo, 2010, Wiens and Zhao, 2007,
Lipkovich and Wiens, 2017]. Yoo [2010] conducted a simulation study for longitudinal
continuous outcome to evaluate type-I error behavior under different amount and types
of missingness. Wiens and Rosenkranz [2013] reported a similar simulation study to
that by Yoo [2010]. Both papers concluded that mixed effect repeated measures con-
trolled type-I error under MAR mechanism. Following that, Lipkovich and Wiens [2017]
evaluated multiple imputation (MI) [Rubin, 2004] for binary response variables in the
NI setting and concluded that MI produces reliable inferences under the MAR assump-
tion. While these simulation studies demonstrate important results, they only consider
limited scenarios. Also, dealing with data MNAR remains an unresolved issue.
The lack of deliberation around the missing data problem is also evident in pub-
lished NI trials. Rehal et al. [2016] reported that over 50% of the published NI trials
6they reviewed between 2010-2015 did not mention any imputation methods used in the
statistical analysis. Similarly, Rabe et al. [2018] showed that 50% of NI and equivalence
articles they reviewed between 2015-2016 used complete case analysis (CCA), a method
that is generally known to produce biased results [Little and Rubin, 2014].
In terms of regulatory guidelines, there seems to be lack of consensus around this
issue as well [Rehal et al., 2016]. The International Conference on Harmonisation (ICH)
guideline for statistical principles for clinical trials [ICH, 1998] mentions missing data
issue and states that imputation methods from very simple to complex may be used for
analysis of incomplete data. The guideline, however, is very broad, and does not explic-
itly discuss analysis of incomplete data for NI design. The extension of Consolidated
Standards of Reporting Trials (CONSORT) 2010 statement [Piaggio et al., 2012] does
not refer to missing data at all. The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 guideline [Chan et al., 2013] recommends using MI
over single imputation and also to perform a sensitivity analysis for missing data. This
guideline is however general for any type of clinical trial and does not specifically refer to
the NI setting. A recent Food and Drug Administration (FDA) guideline for NI clinical
trials [FDA, 2016] includes a very brief statement about missing data: “Imputation of
missing data under the inferiority null hypothesis is one possible approach to countering
the bias due to attrition”. Regulatory guidelines that outline a general framework for
handling incomplete data for any type of clinical study are “Guideline on missing data
in confirmatory clinical trials” [CMPH, 2010] and ”The prevention and treatment of
7missing data in clinical trials” [NRC, 2011]. Both of these guidelines provide a com-
prehensive review of the missing data issue and present methods that could be used to
appropriately analyze incomplete data. However, since the scope of these guidelines is
general, they don’t focus on specific issues that might be relevant for NI trial design.
Also, according to the recent ICH E9(R1) guideline, handling of the intercurrent events,
such as treatment discontinuation is embedded in the estimand’s description [ICH, 2017].
Specifically, the guideline states that occurrence of the intercurrent events in the NI trials
using treatment policy strategy might falsely contribute to apparent similarities between
the treatment groups, and therefore requires “careful reflection” [ICH, 2017].
Following the above, Chapter 2 of this dissertation focuses on different analysis strate-
gies of incomplete data in NI trials under various missingness structures, as well as diverse
set of NI trial scenarios. Specifically, we evaluate the performance of several incomplete
data analysis strategies when assessing difference in binomial proportions. While in the-
ory any type of outcome could be assessed for NI treatment comparison (such as means,
binomial proportions, survival rates, etc.), binomial proportions were recently reported
as the most commonly used outcome in practice. Rabe et al. [2018] reported that (64%)
of the articles they assessed had a binomial outcome for primary analysis. In addition,
Aberegg et al. [2017] reported that 70% of the studies they evaluated, used absolute
risk difference as primary outcome measure. Although an absolute risk differences isn’t
necessarily based on binomial proportions, it is reasonable to assume that the majority
of the studies used it as difference in binomial proportions. According to our own review
8of 189 NI clinical studies published on PubMed between June 2017 and May 2018, we
found that binomial proportions were used in 71 (38%) studies. The difference between
our result and the previously conducted reviews may be due to the somewhat different
search criteria: Aberegg et al. [2017] looked at the high impact factor journals, while
Rabe et al. [2018] randomly selected papers from a bigger pool of publications. Further-
more, the majority (90%) of the studies with binomial outcomes we reviewed assessed
difference in proportions for primary analysis.
There is abundant statistical literature regarding CI construction for difference be-
tween binomial proportions and/or testing difference between two binomial proportions.
Some earlier work includes well known methods by Clopper and Pearson [1934], Fisher
[1935], Barnard [1945], and Pearson [1947], while later methods were developed by New-
combe [1998], Miettinen and Nurminen [1985], Farrington and Manning [1990], Agresti
and Caffo [2000] and many others. In line with previously mentioned FDA recommen-
dation to use CI for NI evaluation, as well as, the variety of the methods available for CI
construction, we first evaluated what are the most commonly used methods for NI trials
in practice. According to our review of 71 NI studies, we found that the most common
methods were Newcombe [1998] (NW) method (13%), generalized linear model (GLM)
approach (11%), Farrington and Manning [1990] (FM) method (10%), and Wald [1943]
method (8%). We also found that 25 (35%) of the reviewed papers didn’t explicitly
specify what method was used for CI construction. It is reasonable to assume that the
majority of these 25 papers used Wald due to its simplicity. Following that, we decided
9to use NW, FM and Wald methods in Chapter 2. GLM approach was not considered,
because unadjusted GLM using the delta method [Reeve, 2018] to estimate the standard
deviation of the difference in proportions has the same form as Wald.
Evaluation of the above methods in NI trials was previously carried out by Dann
and Koch [2008]. The authors concluded, that in terms of type-I error, the choice of the
method would depend on the allocation ratio between the treatment groups. Similar
methods comparison involving Wald CI for difference in binomial proportions for NI
trials was done by Li and Chuang-Stein [2006] and by Almendra-Arao [2009]. In addition,
Brown and Li [2005] who evaluated performance of several methods for constructing CIs
for difference in proportions, which included Wald and NW irrespective of the NI trials
setting, concluded that “all the CIs are doing well” when sample size per arm is at
least 50. Nevertheless, all of the above evaluations were done for fully observed data.
Therefore, comparison between the above methods for incomplete data analysis provides
an important addition to the current literature.
For the analysis strategies in Chapter 2, we used best and worst case scenario im-
putation, CCA and two-stage MI [Shen, 2000, Siddique et al., 2012, 2014]. We provide
a thorough explanation for the choice of the strategies in Chapter 2. Briefly, MI is a
principled, commonly used approach, which could be used for both ignorable and non-
ignorable missingness structures [Rubin, 2004, Sidi and Harel, 2018]. Both, conventional
MI and two-stage MI comprise of imputing the incomplete data several times, analyzing
each complete dataset using a standard statistical procedure and combing the results
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for a final inference [Shen, 2000, Rubin, 2004]. These steps could be easily implemented
for Wald and FM methods as shown in Chapter 2. However, it is not the case for NW
method, for which there were no proper combination rules found in the literature. Fol-
lowing that, we developed proper combination rules for both conventional and two-stage
MI for NW method in Chapter 3.
1.3 Challenges with NI margin choice
As previously mentioned, one of the challenges of NI trials is the choice of clinically ac-
ceptable margin (M2). Although the determination of the margin has been extensively
discussed in the literature [Hung et al., 2003, 2005, 2007, Ng, 2008, Hung et al., 2009,
Hung and Wang, 2013, Liu et al., 2015], the reasons for choosing a specific margin still
remain poorly reported in practice. According to systematic reviews of published NI and
equivalence trials, margin justification was mentioned by 45.7%, 23%, 45%, 42.1% and
38% as reported by Wangge et al. [2010], Schiller et al. [2012], Rehal et al. [2016], Althu-
nian et al. [2017] and Rabe et al. [2018] respectively. These findings underline challenges
associated with the choice of a margin for NI trials. Obviously, just determination of M1
is very complex, since historical data carries publication bias and previously observed
treatment effect embeds some level of uncertainty. However, even if the standard treat-
ment effect is maintained in the current NI study and the study has assay sensitivity,
it is not clear how to choose one number M2, so that it will be clinically acceptable. A
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legitimate question that arises here is the degree of subjectivity of the margin choice.
Would it be sufficient to discuss the margin with only one clinical expert? What if an
investigator who conducts an NI study reaches out to five clinical experts and they all
provide different opinions? How should these opinions be incorporated into the current
practices of design and analysis of the study?
Since knowing the “true”, objective M2 would be extremely helpful for design and
analysis of NI trials, but the “true” margin cannot be observed, we propose to treat it
as missing information. We believe that in order to make proper inferences regarding
non-inferiority of the new treatment compared to a standard of care, while minimizing
subjectivity of the margin choice, it is imperative to conduct a survey upon clinical
experts in this regard. Such survey data can be used to make an informed decision
regarding NI of the new treatment. As a result, the reasons for the margin choice could
be easier communicated to both regulatory authorities and patients who are seeking
alternative treatment options. Moreover, using such survey data regulatory authorities
and public health officials will have a better set of tools to justify or disapprove NI of a
new treatment.
In Chapter 4, we present a general framework for combining results from a clinical
experts survey and NI study. Ideally, the clinical experts survey should consists of a
representative sample of clinicians. Obviously, such an assumption could be violated
in practice by either surveying a very small number of clinicians, and/or by obtaining
opinions of, for instance, more conservative experts. If clinicians conservatism, or lack
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of thereof, in respect to a clinical margin is related to other data for the representative
sample (professional or demographic characteristics of the clinicians), such data could
then be utilized to achieve an objective NI decision. In order to reach this goal, we
propose to use MI approach within the above framework.
1.4 Overall benefit of the new non-inferior treat-
ment
As discussed above, to outweigh a decreased effectiveness, the new non-inferior treat-
ment needs to offer advantages over the standard of care [Piaggio et al., 2012, Wangge
et al., 2013]. Several authors have recommended formal statistical procedures to simul-
taneously evaluate efficacy and safety in NI trials [Bristol, 2005, Ro¨hmel et al., 2006,
Nishikawa et al., 2009]. Bristol [2005] discussed testing simultaneously non-inferiority
of an efficacy endpoint and superiority of a safety endpoint, and recommended using
Max Test defined by the authors. Ro¨hmel et al. [2006] considered a problem with two
primary endpoints, where it was desired to demonstrate non-inferiority of both end-
points with superiority of at least one of them. The authors suggested using a hierarchal
type procedure comprising of the following three steps: 1) test all the endpoints for
non-inferiority, 2) show overall superiority, 3) perform one-sided superiority test of each
endpoint separately. Nishikawa et al. [2009] proposed the union-intersection test of a
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composite endpoint which was defined based on assessing non-inferiority in one end-
point and superiority in another. Also, Gladstone and Vach [2015] introduced a new
concept: advantage deficit assessment, where efficacy reduction is compared to gain in
safety using the advantage deficit ratio.
A shared feature of the above articles is the consideration of two endpoints. However,
during any clinical trial, data on multiple endpoints are being collected and compared
between the therapies under evaluation. A question that arises here is: how can benefits
and risks from a group of endpoints be evaluated, so that the new treatment is beneficial
overall? This question resembles the benefit-risk (BR) topic, which continues to receive a
lot of attention [EMEA, 2009, FDA, 2014, Thokala et al., 2016, Marsh et al., 2016, FDA,
2018, Eichler et al., 2009]. According to “Structured approach to benefit-risk assessment
in drug regulatory decision-making” draft Prescription Drug User Fee Act (PDUFA) V
implementation plan [FDA, 2014], the agency states that for any new treatment to be
approved, it needs to show that its benefits outweigh the risks. Moreover, in “Benefit-risk
assessment in drug regulatory decision making” draft PDUFA VI implementation plan,
the FDA [2018] states not only agency’s intention to conduct a structured BR assessment,
but also mentions importance of incorporating “patient’s voice in drug development and
decision-making in the human drug review program”. The European Medicines Agency
(EMEA) also mentioned the need to shift towards a quantitative BR assessment [Eichler
et al., 2009]. Efforts towards implementation of such assessment are evident from “The
benefit-risk methodology project” by EMEA [2009], that led to publication of several
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working packages [EMEA, 2011, Phillips et al., 2011a,b, 2012, 2014].
Various methods exist for structured BR assessment. Mt-Isa et al. [2016] provides
a summary of systematic reviews in this regard. The authors report on quantitative
methods that were previously reviewed by the following authors: Guo et al. [2010],
Phillips et al. [2011a], Puhan et al. [2012], TORPA [2012], and Mt-Isa et al. [2014]. The
multi-criteria decision analysis (MCDA) was reported as the only method, which was
both reviewed by each of the above authors, and recommended by two, including EMEA
[Phillips et al., 2011a]. The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) issued a two-part report for “MCDA Emerging Good Practices Task
Force” [Thokala et al., 2016, Marsh et al., 2016]. The ISPOR report described MCDA
as a “useful tool” for BR assessment. Moreover, it provided examples of various types
of health care decisions that were supported using MCDA [Thokala et al., 2016], which
underlines the flexibility and generality of this approach.
MCDA for BR assessment of medicines was first introduced by Mussen et al. [2007].
MCDA allows to combine benefit and risk criteria evidence into one overall assessment
measure using scoring and weighting of thereof [Mussen et al., 2007]. The scoring in
MCDA transforms each criteria (outcome value) into a common scale, while weighting
of the criteria specifies a relative importance of each criterion. For NI trials, such overall
assessment measure (MCDA score) could be very useful, since it would allow researchers
to claim overall benefit of a new treatment over a standard of care in spite of decreased
effectiveness in the primary endpoint.
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In Chapter 5, we develop a simple MCDA approach for structured BR assessment
of the new non-inferior treatment when compared to the standard of care using patient
level data from the NI study. With the growing recognition of the importance of pref-
erence elicitation by the patients [Marsh et al., 2017, FDA, 2018] we propose carrying
out such elicitation at the beginning of NI trials. Since patients demographic charac-
teristics and baseline disease status are likely to influence patients outcomes, as well as
patients preferences, we believe that it would be beneficial to study these within the
same trial. The introduction of any questionnaire is likely to increase the burden on the
study participants, and investigators, as well as, on the sponsor conducting the study.
Therefore, we suggest gathering preferences information only on a random sample of the
trial patients, and using MI analysis to create an overall BR assessment. It should be
noted that up to now there is limited evidence regarding the actual use of the patient
preference in the decision-making process for medical product lifecycle [van Overbeeke
et al., 2019].
1.5 Contribution of this dissertation
The main goal of this dissertation is to present innovative methods and practical solutions
to issues faced in the design, analysis, and interpretation of NI clinical trials. Each
Chapter presented here contributes to this goal. In Chapter 2, we provide a set of
recommendations for incomplete data analysis along with a novel approach for analysis
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of data under MNAR. This contributes towards better analysis practices of NI trials.
In Chapter 3, we introduce MI combination rules for difference in binomial proportions,
when the NW method is used. Although we use this method for analysis of NI trials and
therefore contribute towards better analysis of such trials, it is a general methodology
which is useful for other applications as well. In Chapter 4 we present a new framework
for incorporating different clinical experts opinions regarding NI margin into design and
analysis of NI trials. While in Chapter 5, we develop a simple BR assessment approach
for evaluation of overall benefit of non-inferior treatment. Both Chapter 4 and 5 advance
design, analysis and interpretation of NI clinical trials. We hope, that practitioners who
are involved with NI trials would find the research done in this dissertation helpful for
their own work.
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Chapter 2
Incomplete data analysis of NI
clinical trials: difference in binomial
proportions case
2.1 Background
In this Chapter, we focus on incomplete data analysis for NI clinical trials. We assess
the difference in binomial proportions case due to the reasons stated in Chapter 1.
We evaluate best and worst-case scenario imputation, CCA and two-stage MI. Best
and worst-case scenario imputations and CCA strategies were chosen because these are
frequently used in practice for analysis of incomplete NI and equivalence clinical trials
data [Rabe et al., 2018].
Both best-case and worst-case scenario strategies were employed only for the MCAR
missingness mechanism. It was expected that these two strategies would inflate type-I
errors, since they make the two treatment groups more alike, which is anti-conservative in
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NI trials. It is well known that while CCA generates unbiased estimates under MCAR,
it is generally not the case for MAR [Little and Rubin, 2014]. Conventional MI, on
other hand, produces unbiased results under both MCAR and MAR [Little and Rubin,
2014], and therefore is usually recommended over CCA. Despite this, there are still
certain conditions under which CCA would result in unbiased estimates under MAR
and therefore could be safely used [Bartlett et al., 2015]. The advantage of conventional
MI over CCA for NI trials assessing difference in binomial proportions under MAR was
previously shown by Lipkovich and Wiens [2017] in terms of unbiasedness and control of
the type-I error. The authors, however, did not evaluate cases in which CCA provides
unbiased estimates of the treatment effect. Therefore, we explore such conditions here.
In addition, conventional MI may result in biased estimates under MNAR unless relevant
auxiliary variables are included in the imputation model [Collins et al., 2001, Demirtas
and Schafer, 2003]. The inflation of type-I error for NI trials under MNAR, when
analyzed with conventional MI was reported by Lipkovich and Wiens [2017]. To resolve
the issue of type-I error inflation for NI trials under MNAR, we propose using the two-
stage MI procedure described in Section 2.2.
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2.2 Methods
2.2.1 Confidence intervals for difference in proportions
Let Yij ∼ Bernoulli(pi) be an occurrence of a favorable event (such as healing from
a disease) for subject j, in a treatment group i. j = 1 . . . ni, where ni is a sample
size of group i and i = Con, Trt represents control (or standard), and new treatment
respectively. pi is the true proportion of favorable events in group i.
The hypothesis we are interested in testing is of the following form:
H0 : pCon − pTrt ≥M2 vs H1 : pCon − pTrt < M2 , (2.1)
where M2 represents a pre-defined margin as described in Chapter 1, which is assumed
to be positive M2 > 0. H0 will be rejected at the pre-specified α level if the upper bound
of the 100(1 − α)% CI for pCon − pTrt is below M2. As described in Chapter 1, Wald,
FM and NW methods for CI construction were used, since these are the most commonly
used methods in practice.
Let pˆCon =
1
nCon
nCon∑
j=1
YCon,j, pˆTrt =
1
nTrt
nTrt∑
j=1
YTrt,j be maximum likelihood estimates
(MLEs) for pCon, pTrt respectively, and let zα/2 be the upper α/2 quantile of a standard
normal distribution. The approximate 100(1 − α)% CI for pCon − pTrt using the Wald
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method has the following form:
pˆCon − pˆTrt ± zα/2
√
pˆTrt(1− pˆTrt)
nTrt
+
pˆCon(1− pˆCon)
nCon
. (2.2)
The FM method has a similar form to that of Wald’s CI, with the only difference
at the variance term estimation, where p˜Con, p˜Trt are maximum likelihood estimates of
pCon, pTrt respectively under the restriction of the null hypothesis in (2.1) [Farrington
and Manning, 1990]:
pˆCon − pˆTrt ± zα/2
√
p˜Trt(1− p˜Trt)
nTrt
+
p˜Con(1− p˜Con)
nCon
. (2.3)
Finally, the NW method is based on the Wilson’s score method for a single proportion
[Wilson, 1927, Newcombe, 1998]. Let LB,UB be a lower and an upper 100(1− α)% CI
bounds for pCon − pTrt respectively, defined as:
LB = pˆCon − pˆTrt −
√
(pˆCon − lCon)2 + (uTrt − pˆTrt)2 , (2.4)
UB = pˆCon − pˆTrt +
√
(uCon − pˆCon)2 + (pˆTrt − lTrt)2 , (2.5)
where
[lCon, uCon] =
(
pˆCon +
z2α/2
2nCon
± zα/2
√
pˆCon(1− pˆCon)
nCon
+
z2α
4n2Con
)
/
(
1 +
z2α/2
nCon
)
, (2.6)
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[lTrt, uTrt] =
(
pˆTrt +
z2α/2
2nTrt
± zα/2
√
pˆTrt(1− pˆTrt)
nTrt
+
z2α
4n2Trt
)
/
(
1 +
z2α/2
nTrt
)
. (2.7)
2.2.2 Multiple imputation
As mentioned in Chapter 1, MI is a principled approach, which could be applied for
both ignorbale and non-ignorable missingness processes. When the missingness is non-
ignorable, a missingness model needs to be specified. In practice, an exact specification
of such a model is difficult, if not impossible, as it relies on a set of unverifiable assump-
tions. Thus the imputation model could be considered missing, and be multiply imputed
together with subject-level data using two-stage MI [Siddique et al., 2012, 2014]. This
approach incorporates uncertainty associated with both the imputation model and the
imputed subject-level data into the final inference using simple arithmetic combination
rules [Shen, 2000, Reiter and Raghunathan, 2007, Siddique et al., 2012, 2014].
We will drop treatment and patient related indexes for the following description of MI
procedure for simplicity. Let Ycom represent completely observed data, which could be
decomposed into Ycom = (Yobs, Ymis) observed and missing data respectively, and let R be
an indicator specifying when the data are observed/missing. Also, let θ be a parameter
of interest, and φ be a nuisance parameter which characterizes the distribution of the
missing data mechanism (R). The goal is to make inferences about P (Ycom|θ), however,
because some data are incomplete, a missing data mechanism needs to be considered as
well. As a result we have the following joint model:
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P (Ycom, R, θ, φ) = P (Ycom|θ)P (R|Ycom, φ)P (θ, φ) . (2.8)
When using MI, the general imputation model is based on the predictive distribu-
tion of Ymis given observed data Yobs, and missingess indicator (R) using the following
integration of the unknown parameters θ and φ as follows:
P (Ymis|Yobs, R) =
∫∫
P (Ycom, R, θ, φ)
P (Yobs, R)
dθdφ . (2.9)
Replacing the numerator in (2.9) by (2.8), (2.9) becomes:
P (Ymis|Yobs, R) = 1
P (Yobs, R)
∫∫
P (Ycom|θ)P (R|Ycom, φ)P (θ, φ)dθdφ . (2.10)
As described in Chapter 1, under ignorability assumption we have MAR and dis-
tinctness as follows:
P (R|Ycom, φ) = P (R|Yobs, φ) , (2.11)
P (θ, φ) = P (θ)P (φ) . (2.12)
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Substituting (2.11) and (2.12) into (2.10) results in:
P (Ymis|Yobs, R) = P (Ymis|Yobs) . (2.13)
Thus, under the ignorability assumption, instead of imputing from P (Ymis|Yobs, R),
one needs to impute from P (Ymis|Yobs), and “ignore” R. Since, MI commonly imple-
mented using ignorability assumption we will call it “Conventional MI” throughout the
dissertation.
However, if the incomplete data follows a MNAR mechanism, then (2.11) does not
hold and the ignorability assumption is violated. While the violation of ignorability could
also arise from non-distinctness between θ and φ, we will assume that ignorability is vio-
lated by MNAR throughout this dissertation. In this case, the missingness P (R|Ycom, φ)
needs to be modeled. Methods, which were developed specifically for non-ignorable
missingness include: selection models [Heckman, 1976, Amemiya, 1984], pattern mix-
ture models [Little, 1993], and shared parameters models [Daniels and Hogan, 2008].
The main difference between these methods is the factorization of the joint distribution
of (Ycom, R).
In addition, a simple way to generate non-ignorable imputed values (Y nonign) from
ignorable imputed values (Y ign) is using the following transformation as presented by
Rubin [2004]:
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Y nonign = a× Y ign . (2.14)
For example, if a = 1.1, we assume that conditioning on all other observed information,
missing values are still 10% greater than the observed values. Since, in our case the
sample space of Y is (0, 1), instead of using (2.14), we will adjust the probability of
ignorable imputed probability of event (pˆign), to a non-ingorable imputed probability of
event (pˆnonign) as follows:
pˆnonign = a× pˆign . (2.15)
As described by Siddique et al. [2012, 2014], in practice it is impossible to know the
exact imputation model, and therefore it makes sense to take into account uncertainty
associated with the choice of the model. Therefore, following previous work by Siddique
et al. [2012, 2014], we suggest specification of a distribution for a, which corresponds to
specifying a distribution of the imputation model. Such specification needs to be done
by either a study team, or by experts who collect the data.
The imputation model distribution represents the study team’s belief regarding the
magnitude of the bias in the observed rate in treatment group i, and how confident
the team is about this belief. These two values could be seen as the center of the
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missingness model distribution (µai) and its variance (σ
2
ai) respectively. For example,
if the team believes the study participants were more likely to drop-out due to lack of
efficacy in the new treatment, then the team will anticipate that the observed rate in
the new treatment is greater than the actual rate. As a result µa,Trt below 1 for the new
treatment will be chosen, so that the ignorably imputed rate is closer to it’s true value.
If, for the same study, the team believes that the observed rate in the control treatment
is unbiased, then µa,Con = 1 would represent such belief. As a result, there is a separate
imputation model distribution for each treatment group: aCon ∼ N(µa,Con, σa,Con) and
aTrt ∼ N(µa,Trt, σa,Trt) for control and new treatment respectively. We chose to use a
normality assumption on the ai distributions for simplicity, although other distributions
can easily replace the normal distribution. After the imputation model distribution is
specified, we can randomly draw D models from it. Within each of the imputed models,
patient-level data can be imputed L times, resulting in D × L complete datasets.
Using either conventional MI with L complete datasets or two-stage MI with D× L
complete datasets, each of the complete datasets is then analyzed using a standard sta-
tistical method, such as methods presented above. Results from the L, or D×L analyses
are then combined using Rubin’s [Rubin, 2004] or Shen’s [Shen, 2000] combination rules
respectively, as described in the following sections.
Conventional multiple imputation combination rules
Let Q be a quantity of interest, that approximately follows a Normal distribution:
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(Q− Qˆ) ∼ N(0, U) , (2.16)
where Qˆ is a complete data statistic estimating Q, and U is a complete data statistic
for the variance of Q− Qˆ. We will further assume, that the dataset is imputed L times,
so that (Qˆ(l), U (l)) represent the estimate and variance of Q respectively from the lth
imputed dataset (l = 1, . . . , L). Using Rubin’s combination rules [Rubin, 2004], the L
pairs of estimates are then combined as described below.
Let Q¯ be the overall mean of the L estimates:
Q¯ =
1
L
L∑
l=1
Qˆ(l) . (2.17)
Also let U¯ , B be the sources of variability, defined as the overall mean of the associated
variance estimates, and between model variance terms respectively. Specifically:
U¯ =
1
L
L∑
l=1
U (l) , (2.18)
B =
1
L− 1
L∑
l=1
(Qˆ(l) − Q¯)2 . (2.19)
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The overall variance T is then defined as:
T = U¯ + (1 +
1
L
)B . (2.20)
The final inferences of the multiply imputed data are based on Student’s t distribu-
tion:
Q− Q¯√
T
∼ tν , (2.21)
where ν = (L− 1)(1 + U¯
B(1+1/L)
)2.
Two-stage multiple imputation combination rules
The premise specified in (2.16) still holds for the two-stage MI, with the only differ-
ence being that, following D × L imputations, we now have D × L pairs of estimates
(Qˆ(d,l), U (d,l)) (d = 1, . . . , D, l = 1, . . . L) of Q and variance of Qˆ−Q respectively. Using
Shen’s combination rules [Shen, 2000], these pairs of estimates are then combined as
described below.
Let Q¯2 be the overall mean of the D × L estimates:
Q¯2 =
1
DL
D∑
d=1
L∑
l=1
Qˆ(d,l) . (2.22)
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Also let Q¯d be the mean of the estimated from the d
th model:
Q¯d =
1
L
L∑
l=1
Qˆ(d,l) . (2.23)
Let U¯2,W,B2 be the three sources of variability, defined as the overall mean of the
associated variance estimates, within-model and between model variance terms respec-
tively. Specifically:
U¯2 =
1
DL
D∑
d=1
L∑
l=1
U (d,l) , (2.24)
W =
1
D(L− 1)
D∑
d=1
L∑
l=1
(Qˆ(d,l) − Q¯d)2 , (2.25)
B2 =
1
D − 1
D∑
d=1
(Q¯d − Q¯2)2 . (2.26)
Finally, the total variance of Q− Qˆ has the following form:
T2 = U¯2 + (1 +
1
D
)B2 + (1− 1
L
)W . (2.27)
The final inferences of the multiply imputed data are based on Student’s t distribu-
tion:
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Q− Q¯2√
T 2
∼ tν2 , (2.28)
where ν−12 =
[
(1+ 1
D
)B2
T2
]2
1
D−1 +
[
(1− 1
L
)W
T2
]2
1
D(L−1) .
As stated previously, in this part of the dissertation, two-stage MI was used for
MNAR. Therefore, we set Qˆ(d,l) = pˆ(d,l), where pˆ(d,l) is the estimated proportion of
difference between control and new treatment from lth imputation and dth model. For
Wald and FM, the value of U (d,l) was set to the corresponding variance term used in
the method as presented under the square root in (2.2) and (2.3). For NW, Q¯2 for each
treatment group was plugged into (2.4 - 2.7). It should be noted, that in Chapter 3 we
develop a proper method for combining MI results for the NW method.
2.2.3 Simulation study
Simulation of fully observed data
In total, 30 NI clinical trials scenarios were considered. The pCon values were set to
the range between 0.6 and 0.95 by increments of 0.05. The M2 values were set to:
0.05, 0.075, 0.1, 0.15 and 0.2. All possible combinations of the above margins (M2) and
probabilities (pCon) were used, excluding cases where margin was greater or equal to
the corresponding failure rate (1 − pCon). A margin equal to the corresponding failure
rate would mean that the usage of a new treatment doubles a failure rate of the treated
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condition. Therefore, a margin greater or equal to the corresponding failure rate, was
redefined as half of the original margin. Due to the high volume of the results, we present
here only 9 of the 30 scenarios, which are representative of the rest of the results. In
addition, we assumed a one-sided type-I error of 2.5%, power of 90%, and 1:1 group
allocation ratio.
Since different methods for comparison of binomial proportions might require differ-
ent sample sizes [Julious and Owen, 2011], sample sizes were calculated for each method
separately using assumptions of the scenarios above. For Wald and FM methods, the
sample size calculations were performed by inversion of the corresponding CI formulas
[Julious and Owen, 2011], while sample sizes for WN were estimated based on 5000
simulations. As a result the sample size per arm (n) ranged between 98 to 2017 patients
(Appendix A, Figure A1).
The outcome variable Y (subscripts are omitted for simplicity) was simulated for each
subject using a logistic function of treatment group (Grp = 0 for control treatment,
Grp = 1 for the new treatment) and two continuous baseline covariates (X1, X2) as
follows:
P (Y = 1) = [1 + e−(αy+β1∗X1ij+β2∗X2ij+βGrpout∗Grpij)]−1 . (2.29)
Further details regarding parameters setting in the above model are provided in
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(Appendix A, Section A.2). The total number of simulated trials per scenario and
method under each hypothesis was set to 10,000 repetitions. It should be noted, that
increasing the number of repetition did not alter the results.
Simulation of incomplete data
Let Rij be a missing indicator variable for outcome Yij, such that Rij = 1 indicates
that the outcome for patient j in group i is missing while Rij = 0 means that the
outcome for that patient is observed. Upon a generation of the complete datasets, the
missing outcome values were imposed using the following logistic function (subscripts
are omitted for simplicity):
P (R = 1) = [1 + e−(α+βGrp∗Grp+βY ∗Y+βGrpY ∗Grp∗Y+βX2∗X2)]−1 . (2.30)
Parameters βGrp, βY , βGrpY , βX2 represent effects of treatment group, outcome, treat-
ment group by outcome interaction and baseline covariateX2 on missingness respectively.
In order to impose a specific missingness mechanism (MCAR, MAR and MNAR), dif-
ferent parameter values were used. The overall drop-out rates were set to 5%, 10%, 15%
and 20%.
For MCAR, all model parameters but α were set to 0 (α = −log( 1
DO
− 1), DO is a
target drop-out rate). For MAR, βX2 was set to βX2 = 1.5, while βGrp ranged between
-0.9 to 0.9 in order to assess unbalanced levels of drop-out rates of 5-15% between the
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treatment groups. MNAR was set up to implement scenarios where dropping out of the
study is associated with either lack of efficacy in the new treatment or with overwhelming
efficacy in the control treatment, therefore both βY , βGrpY were set to non-zero values.
These two conditions were considered for MNAR, as both would lead to the observed
difference between the treatments appearing smaller than it actually is, which leads to
an incorrect study conclusion.
2.2.4 Analysis Strategies for Incomplete Data
As discussed in Section 2.1, the following strategies were considered for the incomplete
data analysis: best-case and worst-case scenario imputation, CCA and two-stage MI us-
ing multiple imputation chained equations (MICE) [Buuren and Groothuis-Oudshoorn,
2010].
Both best-case and worst-case scenario strategies were employed only for the MCAR
missingness mechanism. It was expected that these two strategies would inflate type-I
errors, since they make the two treatment groups more alike, which in turn makes it
easier to reject the null hypothesis presented in (2.1).
Due to the results provided by Bartlett et al. [2015], it was expected that a CCA
strategy would lead to unabised estimates of pCon and pTrt under MAR, as specified
below (for simplicity we drop the indexes):
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P (Y = 1|X1 = x1, X2 = x2, Grp = i, R = 0) =
P (R = 0|x1, x2, Grp = i, Y = 1)
P (R = 0|x1, x2, Grp = i) P (Y = 1|x1, x2, Grp = i) .
(2.31)
It is easy to see that if P (R = 0|x1, x2, Grp = i, Y = 1) = P (R = 0|x1, x2, Grp = i),
i.e., if missingness of the outcome variable follows MAR process, then:
P (Y = 1|X1 = x1, X2 = x2, Grp = i, R = 0) = P (Y = 1|x1, x2, Grp = i) . (2.32)
For MNAR missingness process, it was expected that single value imputation meth-
ods, or CCA would produce biased results with inflated type-I error rates. Although,
conventional MI might produce unbiased estimates when relevant auxiliary variables are
used [Collins et al., 2001, Demirtas and Schafer, 2003], our simulation set-up did not
address such a situation and therefore we anticipated that conventional MI would not
be able to provide unbiased estimates for MNAR. In order to properly analyze the in-
complete data that follows such missingness process, we used tthe two-stage MI method
described above. Two-stage MI was compared to CCA rather than to conventional MI,
due to the fact that both CCA and conventional MI ought to produce biased estimates
and because CCA is an easy and dominant approach in clinical trials.
As specified in the previous section, two MNAR situations were simulated: drop-out
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due to lack of efficacy in the new treatment and drop-out due to overwhelming efficacy
in the control treatment.
For the first situation, it was expected that the observed rate in the new treatment
group will be higher than it actually is, while the observed rate in the control group will
be unbiased, therefore we specified aTrt ∼ N(µaTrt, 0.05) where µaTrt was chosen below
1 and aCon ∼ N(1, 0). In contrast, in the second situation, it was expected that the
observed rate in the control group was lower than it actually is, while the observed rates
in the new treatment will be unbiased, therefore we set aCon ∼ N(µaCon, 0.05), where
µaCon was chosen above 1 and aTrt ∼ N(1, 0).
Similar to Siddique et al. [2014], L was set to 2, and D was set to 100. The multiple
imputation of the subject-level data within each imputed missingness model (randomly
drawn values of aTrt, aCon) was performed using MICE with the two baseline covariates
specified above. We also performed sensitivity analysis for a, by specifying different
values for µaTrt, µaCon and doubling the standard deviation.
2.2.5 Evaluation Criteria
The Wald, FM and NW performances, along with the analysis strategies used to handle
incomplete data, were assessed using empirical type-I error, empirical power, and mean
relative bias. Type-I error was estimated by the proportion of trials that reject H0
in (2.1) out of the trials simulated under H0 : pCon = M2 + pTrt, and was considered
appropriately controlled if it fell within [0.9α, 1.1α] = [0.0225, 0.0275] bounds [Roebruck
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and Ku¨hn, 1995, Dann and Koch, 2008]. Power was estimated by the proportion of trials
that reject H0 in (2.1) out of the trials simulated under H1 : pCon = pTrt. A relative bias
was defined under H0 : pCon = M2 + pTrt as (pˆCon − pˆTrt −M2)/M2 per repetition. A
result was considered unbiased if the mean relative bias fell within [−0.1, 0.1] bounds.
The negative bias implies that the new treatment (Trt) is worse than it appears, thus a
non-inferiority of the new treatment may be incorrectly inferred.
The simulations presented in this Chapter, as well as in the following Chapters of the
dissertation were done using R with reproducible code available on the author’s github
page.
2.3 Results
2.3.1 Missing completely at random
Table 1 presents empirical type-I errors, and mean relative bias for MCAR data under
different study scenarios, as well as empirical type-I errors for fully observed data. Re-
sults presented in this table correspond to overall drop-out rate of 20%, as these are
representative for lower drop-out rates. Also, since the three CI methods showed very
similar results, only the Wald method is presented for MCAR. Columns “Full”, “Worst”,
and “CCA” under “Type-I” in the Table 1 correspond to the empirical type-I error re-
sults for fully observed data, incomplete data analyzed using worst-case imputation, and
CCA strategies respectively. Also columns “Worst”, and “CCA” under “Bias” in the
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Table 1 correspond to the mean relative bias results for incomplete data analyzed using
worst-case imputation and CCA strategies respectively. For example, the first row of
Table 1 corresponds to the scenario in which pCon is 0.65, M2 is 0.05, the type-I error of
the completely observed data is 0.026, while the type-I error for incomplete data ana-
lyzed using worst-case imputation is 0.103 with mean relative bias of -0.214, and type-I
error for CCA is 0.029 with mean relative bias of -0.019. As can be seen across different
scenarios in Table 1, the worst-case scenario imputation strategy produced inflated type-
I error rates that were more than double that of the completely observed data, along
with significantly biased estimates. In contrast, CCA produced unbiased estimates with
type-I errors being either within the pre-specified range of [0.0225, 0.0275] or very close
to it.
Table 1: Empirical type-I errors and mean relative bias for MCAR, DO=20%, worst-case
imputation scenario and CCA strategies, Wald method
Type-I Bias
pCon M2 Full Worst CCA Worst CCA
0.65 0.05 0.026 0.103 0.029 -0.214 -0.019
0.65 0.10 0.027 0.093 0.028 -0.210 -0.016
0.65 0.15 0.025 0.090 0.026 -0.211 -0.015
0.75 0.05 0.025 0.079 0.026 -0.201 -0.002
0.75 0.10 0.026 0.087 0.029 -0.205 -0.004
0.75 0.15 0.023 0.084 0.025 -0.209 -0.009
0.80 0.15 0.024 0.074 0.026 -0.212 -0.011
0.85 0.05 0.023 0.066 0.024 -0.194 0.008
0.85 0.10 0.028 0.067 0.026 -0.198 0.003
Due to the significant inflation of type-I error for worst-case imputation method,
empirical power was calculated for the CCA strategy only. As expected, the power
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decreases with higher drop-out rates, dropping to 81.5% (Appendix A, Figure A2).
Results for best-case scenario imputation were very similar to the worst-case scenario
and therefore are omitted.
2.3.2 Missing at random
Figure 2 presents results from 9 scenarios for empirical type-I errors under MAR with
balanced drop-out rates, analyzed using CCA. Each box in the Figure corresponds to a
different scenario as specified in the grey title at the top of the box. For instance, the
top right box corresponds to the scenario with M2 = 0.05, pCon = 0.85, and n = 1071.
In addition, the dashed lines in each box represent bounds for contorlled type-I error,
as specified in Section 2.2, and different dot colors represent different CI construction
methods. If a dot lies within the dashed lines, it means that the type-I error is controlled.
As can be seen in Figure 2, empirical type-I errors were well controlled in most of the
scenarios by the three methods. In addition, this strategy (CCA) resulted in unbiased
estimates, while the empirical power went down to 81.7% (Appendix A, Figure A3). For
unbalanced drop-out rates, as expected CCA showed slight deviations from the desired
level of the type-I error, with maximal empirical type-I error equal to 0.0419 for the
overall drop-out rate of 20%, when the drop-out rates between the treatment groups
differed by 15% (Appendix A, Figure A4). Nevertheless, the mean relative bias fall
within the specified bounds for all of the scenarios, methods, and drop-out rates (results
for balanced drop-out rates and overall 20% drop out rates are presented in Appendix
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A, Figures A5 and A6).
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Figure 2: Empirical type-I error CCA strategy for MAR: drop-out rates are balanced
between the treatment groups
2.3.3 Missing not at random
Figures 3 and 4 have a similar representation to that of Figure 2 above, and show
empirical type-I errors rates for incomplete data under MNAR due to lack of efficacy in
the new treatment analyzed using CCA and two-stage MI respectively. As can be seen
in Figure 3, empirical type-I errors were seriously inflated when analyzed using CCA.
However, as shown in Figure 4, this was not the case for two-stage MI, which produced
type-I errors either within the specified bounds or very close to them. In addition, for
two-stage MI, the NW method has shown less favorable results compared to the Wald
and FM approaches. To further demonstrate advantages of two-stage MI over CCA
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for MNAR, we present mean relative bias in Table 2 for drop-out rate of 20% when
using Wald method. The corresponding mean relative bias results for the other two
methods were similar to Wald and therefore are omitted here. The first two columns of
the Table (pCon and M2) correspond to the scenario assumptions, i.e. event probability
in the control treatment and clinically acceptable margin respectively. The later two
columns of the Table correspond to mean relative bias following analysis using CCA and
two-stage MI, with values below -0.10 indicated biased estimates as specified in Section
2.2. For example, when pCon is 0.65 and M2 is 0.05, the mean relative bias with CCA
strategy is -0.897, while it is only -0.032 with two-stage MI. Overall, as can be seen in
Table 2, the CCA strategy produced biased results for all the scenarios, while two-stage
MI resulted in unbised estimates. In addition, while the mean relative bias was of a
smaller magnitude for lower drop-out rates, CCA still resulted in biased estimates in
most cases, while two-stage MI showed unbiased estimates (Appendix A, Table A1).
The empirical power based on the two-stage MI was below the desired level of 0.9 with
a lowest rate of 65.8% for overall drop-out rate of 20% (Appendix A, Figure A7). This
is not surprising due to variability introduced through the MI procedure. Results from
MNAR due to overwhelming efficacy in the control treatment were similar in terms of
type-I errors, bias and power to the MNAR due to lack of efficacy in the new treatment
(Appendix A, Figures A8-A10, and Table A2).
In addition, it should be noted that the only scenario (out of 30), which produced
unfavorable results for MNAR when the drop-out rates are due to lack of efficacy in
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Figure 3: Empirical type-I errors, CCA strategy for MNAR due to lack of efficacy in
Trt
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Figure 4: Empirical type-I errors, two-stage MI strategy via MICE for MNAR due to
lack of efficacy Trt
the new treatment and the analysis strategy is two-stage MI was the scenario with the
highest pCon and lowest M2 (pCon = 0.95, M2 = 0.025). The comparison between the
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Table 2: Mean relative bias for MNAR due to lack of efficacy in Trt, DO=20%, CCA
and two-stage MI strategies, Wald method
pCon M2 CCA MI
0.65 0.05 -0.897 -0.032
0.65 0.10 -0.453 0.015
0.65 0.15 -0.300 0.022
0.75 0.05 -0.852 -0.038
0.75 0.10 -0.458 0.000
0.75 0.15 -0.319 0.055
0.80 0.15 -0.328 0.019
0.85 0.05 -0.709 -0.068
0.85 0.10 -0.422 -0.001
type-I error rates, as well as mean relative bias between the two analysis strategies for
MNAR due to lack of efficacy in Trt using different methods and different drop-out rates
is presented in Table 3. For example, the empirical type-I error for 5% drop-out with FM
method was 0.086 when analyzed using CCA and 0.044 when analyzed with two-stage
MI. Overall, as can be seen in Table 3, the results from two-stage MI performed better
than CCA.
In Figure 5, we present a sensitivity analysis for the choice of distribution of imputa-
tion models specified by multiplier aTrt. Although type-I error rates are affected by the
choice of the imputation model distribution, in all the cases the type-I errors are much
smaller than the one observed for CCA strategy (solid black horizontal line).
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Table 3: Empirical type-I errors and mean relative bias for scenario with pCon =
0.95, M2 = 0.025, MNAR due to lack of efficacy in Trt.
Method DO Strategy Empirical type-I error Mean relative bias
FM 5% CCA 0.086 -0.206
FM 5% MI 0.044 -0.106
Wald 5% CCA 0.090 -0.206
Wald 5% MI 0.044 -0.106
NW 5% CCA 0.086 -0.207
NW 5% MI 0.054 -0.108
FM 10% CCA 0.199 -0.392
FM 10% MI 0.051 -0.195
Wald 10% CCA 0.209 -0.392
Wald 10% MI 0.052 -0.195
NW 10% CCA 0.210 -0.395
NW 10% MI 0.096 -0.196
FM 15% CCA 0.359 -0.548
FM 15% MI 0.039 -0.252
Wald 15% CCA 0.360 -0.549
Wald 15% MI 0.042 -0.252
NW 15% CCA 0.363 -0.552
NW 15% MI 0.141 -0.256
FM 20% CCA 0.497 -0.678
FM 20% MI 0.027 -0.289
Wald 20% CCA 0.493 -0.676
Wald 20% MI 0.026 -0.284
NW 20% CCA 0.499 -0.681
NW 20% MI 0.168 -0.290
2.4 Conclusion
In this Chapter, we present a thorough simulation study assessing different strategies for
analysis of incomplete data when an NI design is employed and the outcome of interest
is difference in binomial proportions. We evaluated three commonly used methods for
construction of confidence intervals for the difference in binomial proportions: Wald,
NW and FM.
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Figure 5: Choice of different distribution parameters for aTrt. Empirical type-I error,
two-stage MI strategy via MICE for scenario with pCon = 0.85,M2 = 0.1 for MNAR due
to lack of efficacy in Trt using Wald.
We found that both best/worst-case imputation strategies perform poorly even when
the incomplete data follows MCAR. This is due to the fact that, by treating incomplete
cases similarly for both treatment groups, we make the estimated proportions simi-
lar, which leads to erroneous conclusion of NI. According to Rabe et al. [2018] 28% of
the reviewed articles that encountered some amount of incomplete data in the primary
analysis, used single imputation strategy, including best/worst-case imputation. The
simulation results we present here along with the review results reported by Rabe et al.
[2018] are concerning. We believe that such an imputation strategy should be abandoned
when dealing with NI analysis.
Similar to previous work by Bartlett et al. [2015], we found that CCA performs
well when incomplete data follows MAR, and both baseline covariates that affect the
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missingness and the corresponding drop-out rates are balanced between treatment arms.
In addition, when the drop-outs rates were higher in the new treatment, type-I errors
might be inflated, depending on the scenario. Among cases with unbalanced drop-out
rates, the highest type-I error rate that was seen is 0.0419% for overall drop-out rate of
20% with 15% higher drop-out in the new treatment. Considering the levels of inflations
seen for MNAR and the fact that the 0.0419% rate was reached by a relatively extreme
missingness scenario, we believe that CCA could still be considered as a safe choice
for MAR incomplete data. It should be noted that if researchers assume that MAR
is affected by variables that have different levels between the treatment groups, then
a conventional MI strategy is recommended over CCA, as suggested by Lipkovich and
Wiens [2017]. The importance of the findings for MAR presented here, is to demonstrate
when CCA could be used and what assumption needs to be made in order to have a
valid inference.
Importantly, we demonstrate that while CCA performs poorly for incomplete data
under MNAR, which is also the case for conventional MI [Lipkovich and Wiens, 2017],
two-stage MI strategy produces favorable results. These results are of great importance
for practitioners who encounter incomplete data in NI clinical trials. The limitation of
this method is the specification of the distribution of the multiple imputation model,
or the multiplier. Nevertheless, according to the sensitivity analysis we performed, it is
clear that even if the parameters of the multiplier’s distribution are shifted, the type-I
error rates are still substantially lower than those seen with CCA strategy.
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The results of the empirical power were in line with our expectation. In general,
empirical power decreased with increasing drop-out rates. In terms of the difference
between the analysis methods considered here, we found that in most cases there was
no difference between the three. However, when the two-stage MI procedure was used,
NW performed worse than Wald and FM. This could be explained by the fact that we
used a plug-in method for NW, rather than a proper MI combination rules. In Chapter
3, we present a solution for this issue and show that once implemented the results of
NW become closer to the other two methods.
Although, we have looked at a variety of different scenarios, one the the limitations
of our work is that it does not cover all possible scenarios. Therefore, before finalizing
statistical analysis plan for NI trial, researchers should always consider a specific scenario
they are dealing with. Another limitation of our work it that the sample sizes that were
considered are moderate to large. We have not evaluated small sample sizes which
might require exact methods, such as a method due to Chan [1998], and thus might
have different implications when applying MI strategy.
In summary, we recommend employing the following analyses strategies when dealing
with incomplete data for NI trials assessing difference in binomial proportions: 1) if the
incomplete data follow MAR and it is reasonable to assume that the missingness is
caused by balanced baseline covariates only, then CCA could be used, 2) if the data are
MAR, but the missingness is caused by other unbalanced variables then following the
work by Lipkovich and Wiens [2017] conventional MI should be used, 3) if MNAR is
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a more reasonable assumption, then two-stage MI should be used, 4) worst/best-case
imputation should be avoided.
The main contribution of this Chapter lies within the above recommendations, which
advocate for better analysis practices of NI trials. We believe that these are useful for
practitioners who face incomplete data analysis of NI trials that assess difference in
binomial proportions.
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Chapter 3
Difference between binomial
proportions using Newcombe’s
method with multiple imputation
for incomplete data
3.1 Background
As discussed in Chapter 2, if one decides to use the NW method to analyze differences
in binomial proportions, and applies an MI procedure due to incomplete data, there are
no combination rules to properly estimate the final CI.
The NW method is an extension of the Wilson’s score method [Wilson, 1927] for CI
construction for one binomial proportion. A similar issue to the above proper combina-
tion rules following MI procedure was discussed by Lott and Reiter [2018] for Wilson’s
method. The authors presented simulation results for MCAR and MAR missingness
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mechanisms. Here, we present a proper MI procedure for the NW (MI-NW) method
for estimating CI for difference between two proportions, not only for MCAR and MAR
but also extend it for MNAR. We compare the NW-MI method developed here with the
methods used in Chapter 2, i.e., Wald, FM, and a plug-in NW method (NW-plug).
3.2 Methods
Similar to Chapter 2, Yij ∼ Bernoulli(pi) is an occurrence of a favorable event for subject
j, in a treatment group i (j = 1 . . . ni, i = Con, Trt), and pi is the true proportion
of favorable events in group i. Also, pˆCon, pˆTrt correspond to the MLEs of pCon, pTrt
respectively as defined in Chapter 2.
As mentioned above, the NW method is based on the Wilson score method for one
proportion [Wilson, 1927]. Specifically, it is assumed that the following large sample
approximation holds: pˆi|pi ∼ N(pi,
√
pi(1− pi)/ni), which in turn implies that:
P (−zα/2 < pˆi − pi√
pi(1− pi)/ni
< zα/2) = 1− α . (3.1)
By squaring the term inside the probability in (3.1) and subsequently solving the
quadratic equation for pi, one can get the lower and upper bounds of the CI for pi as
presented in (2.6) and (2.7) for treatment Con and Trt respectively.
The derivation by Lott and Reiter [2018] is based on (3.1). The authors replaced
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the zα/2, pˆi, pi, and the denominator pi(1 − pi)/ni from (3.1) with t, Q¯i , Qi, and
Ti respectively. Q¯i , Qi, and Ti come from (2.21) after adding a subscript i for each
treatment group, and t is the upper α/2 quantile of tν distribution in (2.21). As a
result the authors presented the following formula for proper combination rules for one
binomial proportion using Wilson’s method after MI:
2Q¯i +
t2
ni
+ t
2ri
ni
2(1 + t
2
ni
+ t
2ri
ni
)
±
√√√√(2Q¯i + t2ni + t2rini )2
4(1 + t
2
ni
+ t
2ri
ni
)2
− Q¯
2
i
1 + t
2
ni
+ t
2ri
ni
, (3.2)
where ri =
(1+1/L)Bi
U¯i
and U¯i, and Bi were previously defined in (2.18) and (2.19) respec-
tively.
3.2.1 Multiple imputation Newcombe interval - ignorable miss-
ingness
For ignorable missingness, we propose to construct CI for difference between two propor-
tions using a NW-MI method by first performing MI under ignorable assumption as de-
scribed in Chapter 2 for each group separately, and thus obtaining values Q¯Trt, rTrt, Q¯Con,
rCon, which can then be used in (3.2) to obtain lower and upper bounds (qli, qui re-
spectively) for each MI estimated proportion for pCon and pTrt. Similar to the origi-
nal Newcombe’s method for completely observed data [Newcombe, 1998], the resulting
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qlTrt, quTrt, qlCon, quCon are then used in (2.4) and (2.5) as lTrt, uTrt, lCon, uCon respec-
tively along with pˆi = Q¯i to estimate the CI for difference between two proportions
pCon − pTrt for the NW-MI method.
3.2.2 Multiple imputation Newcombe interval - nonignorable
missingness
For non-ignorable missingness, we propose to use two-stage MI described in Chapter 2.
Similar to the previous section, we perform two-stage MI for each group separately and
obtain CIs for pCon and pTrt. The lower and upper bounds of these CIs are then used to
construct a CI for the difference between proportions.
Let’s start by first introducing a properly constructed CI for one proportion using the
Wilson method with two-stage MI. It should be noted that our derivations are closely
related to, and use similar notation, as in Lott and Reiter [2018]. For simplicity we
drop subscript i in the following derivations. Based on the result of combination rules
of two-stage MI in (2.28), a (1− α)100% CI for Q is defined as:
P (−t2 ≤ Q− Q¯2√
T2
≤ t2) = 1− α , (3.3)
where t2 is an upper α/2 quantile of tν2 distribution in (2.28). Next we square the inside
probability terms in (3.3), and substitute T2 as defined in (2.27). As a result we obtain
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the following inequality:
(Q− Q¯2)2
U¯2 + (1 +
1
D
)B2 + (1− 1L)W
≤ t22 . (3.4)
Then by using the following: r2 =
(1+1/D)B2
U¯2
and s = (1−1/L)W
U¯2
, we have:
(Q− Q¯2)2
U¯2(1 + r2 + s)
≤ t22 . (3.5)
According to Rubin [2004] it is reasonable to assume that U¯2 ≈ U . Since in the one
proportion binomial case we have U = p(1− p)/n = Q(1−Q)/n, (3.5) becomes:
(Q− Q¯2)2
(Q(1−Q)/n)(1 + r2 + s) ≤ t
2
2 . (3.6)
By solving (3.6) for Q we get the following lower and upper bounds (q2l, q2u respec-
tively) for p:
2Q¯2 +
t22
n
+
t22r2
n
+
t22s
n
2(1 +
t22
n
+
t22r2
n
+
t22s
n
)
±
√√√√(2Q¯2 + t22n + t22r2n + t22sn )2
4(1 +
t22
n
+
t22r2
n
+
t22s
n
)2
− Q¯
2
2
1 +
t22
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n
. (3.7)
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As a result, (3.7) represents a proper CI for one proportion using the Wilson method
with two-stage MI. Based on this equation, one can construct a CI for NW-MI method
for difference between two proportions using (2.4) - (2.8). Specifically, let’s assume two-
stage MI is used to estimate CIs for pCon and pTrt separately using (3.7). Thus, we
obtain lower and upper CI bounds for pCon (q2lCon and q2uCon respectively) and pTrt
(q2lTrt and q2uTrt respectively). The values q2lTrt, q2uTrt, q2lCon, q2uCon are then used
as lTrt, uTrt, lCon, uCon in (2.4) and (2.5), respectively to obtain lower (LB) and upper
bound (UB) of CI for difference between two proportions pCon − pTrt.
It should be noted that for NW, MI prefix indicates that a multiple imputation
procedure based on either ignorable or non-ignorable assumption was implemented.
3.2.3 Simulation studies
In order to assess the performance of NW-MI method developed here and compare it to
the other three methods used in Chapter 2 we used simulation studies with the following
set-up: pCon ∈ {0.65, 0.9}, pTrt = pCon −M2, M2 ∈ {0.025, 0.1}, ni ∈ {100, 500}, and it
was assumed that nTrt = nCon. The values of pCon and M2 were chosen to represent both
mid-range and high value probabilities with small and moderate differences between the
two proportions. The sample size values where chosen to assess the impact of moderate
and large samples per group. In addition, drop-out (DO) rates were assumed to be
balanced between treatment groups and were set to induce both low (10%) and moderate
(30%) rates. As a result, we had 16 different scenarios for all possible combinations of
53
the above specifications. The α level was set to 5%. Simulations were repeated 10,000
times for each scenario. It should be noted, that increasing the number of repetition did
not alter the results.
Let Rij be a missingness indicator with Rij = 1, when Yij is missing and Rij = 0,
when Yij is observed. In the following sections we explain how MCAR, MAR and MNAR
were specified and analyzed.
MCAR - simulation and analysis
MCAR missingness structure was imposed by randomly masking the values of Y to
achieve P (Rij = 1) = DO. The incomplete data were multiply imputed based on
the ignorability assumption. In other words, it was sufficient to use only observed
values of Yij in order to determine the distribution of the incomplete values of Yij, and
thus properly impute them. It should be noted that in our case the determination of
the distribution of incomplete values of Yij essentially means specifying p
∗
i = P (Yij =
1|Rij = 1) correctly, so we can impute these values based on Bernoulli(p∗i ) distribution.
We assumed a non-informative prior for pi ∼ U(0, 1), so that the posterior distribution
of pi was Beta(ai, bi), where ai is number of ones in group i plus one and bi is a number
of observed zeros in group i plus one. The value of p∗i was then randomly drawn from
Beta(ai, bi), and was used to determine the values of Yij for incomplete observations
using Bernoulli(p∗i ) distribution. Within each imputation, we used 1000 iterations of
Gibbs sampling to achieve convergence to a stable stationary distribution of p∗i . In total
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we repeated this procedure L = 10 times, which resulted in 10 complete datasets, similar
to the number of imputations used by Lott and Reiter [2018]. As part of the sensitivity
analysis, we increased the number of imputations to 20, which did not alter the results.
Following the MI procedure, CI’s for different methods were constructed as described
above for NW-MI and in Chapter 2 for the other three methods.
MAR - simulation and analysis
In order to impose MAR, an additional categorical variable X was defined. Similar to
Lott and Reiter [2018], we used two types of MAR, first we assumed strong association
between X and Y , specified as follows (subscripts are dropped for simplicity): P (X =
1|Y = 1) = 0.2, P (X = 1|Y = 0) = 0.6. Then we assumed independence between X
and Y by specifying: P (X = 1|Y = 1) = P (X = 1|Y = 0) = 0.6. Due to the ignorable
missigness imposed here, MAR was imputed using the same procedure as describe for
MCAR for each value of X separately. Also, the construction of CIs was done similarly
to those done for MCAR imputed data.
3.2.4 MNAR - simulation and analysis
For MNAR, missingness was specified by making probability of missingness depend on
the outcome values for group Con as following:
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P (RCon,j = 1|YCon,j = 0) = P (RCon,j = 1)− P (RCon,j = 1|YCon,j = 1)P (YCon,j = 1)
P (YCon,j = 0)
,
where P (RCon,j = 1|YCon,j = 0) was set to be smaller than P (RCon,j = 1|YCon,j = 1),
and P (RCon,j = 1) = DO. The probability of missingness for group Trt was set to
be independent of the Y values, i.e. P (RTrt,j = 1) = DO. As a result, the observed
difference between the estimated proportions would appear to be smaller than it actually
is.
In the situation presented here, it is clear that MI using the ignorable assumption
would not result in proper inferences. This is due to the fact that the observed difference
between the proportions would be biased as described above, whereas the unobserved
information is the source of such bias. To demonstrate this we performed MI using both
ignorable and non-ignorable assumptions. For the ignorable assumption, we simply
followed the procedure described in Section 3.2.3, since the missingness was generated
only using values of Y . For non-ignorability, we used a two-stage MI procedure as
follows.
As presented in (2.15), we can adjust an event probability estimated under ignorable
assumption (pˆigni ) by using some constant multiplier a, so that pˆ
nonign
i will represent
probability estimated under non-ignorable assumption. The incomplete data is again
imputed for each group separately, therefore we specify ai as multiplier for group i. In
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general, specifying different multipliers per group separately allows us to assume different
missingness models for the groups, a situation that is not uncommon in practice. First we
set a distribution for ai as ai ∼ N(µi, σi). Since missingness for group Trt is essentially
ignorable we specify aTrt ∼ N(1, 0). For group Con, based on (2.15) µCon can be defined
as a link between a probability of a favorable event based on observed and non-observed
values as (the subscripts are omitted for simplicity):
P (Y = 1|R = 1) = µCon × P (Y = 1|R = 0) .
Moreover, it is easy to see that:
P (Y = 1|R = 1) = P (Y = 1)− P (Y = 1|R = 0)P (R = 0)
P (R = 1)
, (3.8)
and
P (Y = 1) =
P (R = 0)P (Y = 1|R = 0)
P (R = 0)
. (3.9)
inserting (3.9) into (3.8) gives us:
µCon =
P (Rij = 0)
P (Rij = 1)P (Rij = 0|Yij = 1) −
P (Rij = 0)
P (Rij = 1)
. (3.10)
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The value of σCon ranged between 0.03 to 0.26 and was calibrated through simulation
of the 10,000 repeated samples that were generated for MNAR missingness process.
Specifically, within each repeated sample, we calculated the expression that appears in
(3.10), and σCon was set to be a standard deviation for these 10,000 values within each
scenario.
The values of ai’s were then randomly drawn D times from the distribution specified
above. In addition, we estimated pˆigni L times using the MI procedure presented in
Section 3.2.3, so that pˆigni = p
∗
i . Then, L values of pˆ
ign
i were multiplied by D values
of ai’s, so that we received D × L pˆnonigni values. Incomplete values of Yij were then
determined by Bernoulli(pˆnonigni ) distribution. As a result we received D × L complete
datasets and used two-stage MI combination rules described in Chapter 2 to summarize
them. Similar, to Siddique et al. [2012], two-stage MI for MNAR was performed using
D = 100, L = 2.
3.2.5 Evaluation criteria
The initial evaluation criteria included coverage probability, average interval width, per-
cent of cases where the interval fell outside the range of [−1, 1], and percent of cases with
zero width. Since, after completing all the simulations, we did not encounter any cases
where the interval either fell outside [−1, 1] or had zero width intervals, these evaluation
criteria are not be presented. A procedure was considered as favorable if it’s coverage
probability achieved the desired α level. Among favorable procedures, a procedure with
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the shortest CI width would be considered more advantageous. Coverage probability
was calculated as the number of times the true difference M2 fell inside the 95% CI
divided by 10,000 repetitions.
3.3 Results
Table 4 presents coverage probabilities for fully observed data for each simulation sce-
nario and method. For example, for pCon = 0.65, M2 = 0.025 and n = 100, the coverage
probability for Wald was 0.9476. As can be seen in Table 4, the coverage probability
of the fully observed data reached the desired rate of 95% for all the methods. Table
5 presents average widths of the 95% CIs for fully observed data for each simulation
scenario and method. For example, for pCon = 0.65, M2 = 0.025 and n = 100, the
average width for Wald was 0.265. As can be seen in Table 5, the average width of the
95% CIs were similar between the methods for the fully observed data.
Table 4: Coverage probability for fully observed data
pCon M2 n Wald FM NW
0.65 0.025 100 0.9476 0.9502 0.9502
0.90 0.025 100 0.9455 0.9483 0.9541
0.65 0.10 100 0.9475 0.9489 0.9489
0.90 0.10 100 0.9478 0.9481 0.9513
0.65 0.025 500 0.9526 0.9530 0.9528
0.90 0.025 500 0.9501 0.9507 0.9515
0.65 0.10 500 0.9478 0.9495 0.9495
0.90 0.10 500 0.9479 0.9482 0.9488
Figure 6 shows coverage probabilities for all the scenarios and methods under MCAR.
59
Table 5: Average width of 95% CI for fully observed data
pCon M2 n Wald FM NW
0.65 0.025 100 0.265 0.266 0.261
0.90 0.025 100 0.174 0.174 0.180
0.65 0.100 100 0.269 0.270 0.264
0.90 0.100 100 0.194 0.195 0.198
0.65 0.025 500 0.119 0.119 0.119
0.90 0.025 500 0.078 0.078 0.079
0.65 0.100 500 0.121 0.121 0.120
0.90 0.100 500 0.087 0.088 0.088
The dashed line on the Figure represents the desired coverage probability of 0.95, and
the dotted line represents coverage probability of 0.90. The drop-out rates correspond
to different colors, and sample size is represented by different shapes. A method is
considered to perform well, if its coverage probability is on the dashed line or close to
it. As can be seen on Figure 6, NW-MI, Wald and FM show coverage rates close to the
desired level. Importantly, the three methods outperform NW-plug, which has coverage
rates between 89.2% to 90.4% for drop-out rate of 30%, and between 93.3% to 94.3% for
drop-out rate of 10%. Average CI widths for MCAR are presented in Figure 7, as can be
seen NW-plug had a shorter CI width than the other methods across all the scenarios.
Figure 8 has a similar presentation as Figure 6, and shows coverage probabilities for
MAR with highly correlated X and Y . As can be seen in Figure 8, NW-plug showed
coverage rates below 90% for drop-out rates of 30% for most of the scenarios, while the
coverage rates for drop-out of 10% were between 92.8% and 94.1%. In contrast, NW-MI,
Wald and FM demonstrated coverage probabilities which either achieved or were above
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Figure 6: Coverage probability for MCAR (Dashed line represents the desired coverage
probability of .95, dotted line represents covarage probability of .90.)
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Figure 7: Average width of 95% confidence intervals for MCAR
the desired level of 95%. Average CI widths for MAR with highly correlated X and Y
are presented in Figure 9. As can be seen in Figure 9, similarly to MCAR, the average
CI widths were shorter with MI-plug than with the other methods. Results for MAR
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with independent X and Y are similar to the results for MAR with highly correlated X
and Y , and therefore are presented in Appendix B (Figures B1, B2).
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Figure 8: Coverage probability for MAR with highly correlated X and Y (Dashed line
represents the desired coverage probability of .95, dotted line represents coverage probability
of .90.)
As stated previously, MNAR data were analyzed using the non-ignorable assumption.
Figure 10 has similar presentation to that of Figure 6, and shows coverage probabilities
for MNAR. As can be seen in Figure 10, the coverage rates for the drop-out of 10%
were at or close to the desired level of 95% for NW-MI, Wald, and FM methods, while
these were between 92.7% and 94.3% for NW-plug. For the 30% drop-out, the coverage
probability ranged between 92% and 94.5% for FM, between 92% and 94.2% for MI-
Wald, between 91.3% and 93.9% for MI-NW, and between 84.5% and 89.4% for MI-plug
(Figure 10). Average CI widths results were again similar to the ones produced for
previous missingness mechanisms (Appendix B, Figure B3).
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Figure 9: Average width of 95% confidence intervals for MAR with highly correlated X
and Y
In order to demonstrate advantages of non-ignorable NW-MI over the ignorable one
under MNAR, we present coverage rates of these approaches for all the simulation sce-
narios and drop-out rates in Table 6. In addition, the last column in the Table shows
differences between the coverage probabilities obtained from non-ignorable MI and the
coverage probabilities obtained from ignorable MI, so that a positive difference indicates
a higher coverage for non-ignorable MI. For example, when pCon = 0.65, M2 = 0.10, n =
500, DO = 0.30, the coverage rate with non-ignorable MI is 74.2% higher than the cor-
responding coverage rate with ignorable MI. As can be seen in Table 6, the coverage
rates obtained from non-ignorable MI were closer to the nominal coverage of 95% than
those based on ignorable MI for all scenarios.
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Figure 10: Coverage probability for MNAR analyzed based on non-ingorable assumption
(Dashed line represents the desired coverage probability of .95, dotted line represents coverage
probability of .90.)
Table 6: Comparison of coverage probabilities estimated under non-ignorability and
ignorability assumption for MNAR using NW-MI method
pCon M2 n DO CP non-ignorable MI CP ignorable MI CP difference
0.65 0.025 100 0.10 0.9442 0.9330 0.0112
0.65 0.025 100 0.30 0.9187 0.7451 0.1736
0.65 0.025 500 0.10 0.9414 0.8777 0.0637
0.65 0.025 500 0.30 0.9131 0.1640 0.7491
0.65 0.10 100 0.10 0.9432 0.9317 0.0115
0.65 0.10 100 0.30 0.9259 0.7449 0.1810
0.65 0.10 500 0.10 0.9486 0.8815 0.0671
0.65 0.10 500 0.30 0.9197 0.1776 0.7421
0.90 0.025 100 0.10 0.9535 0.9530 0.0005
0.90 0.025 100 0.30 0.9331 0.9263 0.0068
0.90 0.025 500 0.10 0.9455 0.9358 0.0097
0.90 0.025 500 0.30 0.9209 0.7680 0.1529
0.90 0.10 100 0.10 0.9520 0.9505 0.0015
0.90 0.10 100 0.30 0.9394 0.9253 0.0141
0.90 0.10 500 0.10 0.9488 0.9418 0.0070
0.90 0.10 500 0.30 0.9354 0.7956 0.1398
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3.4 Conclusion
In this Chapter, we extended the previously developed proper combination rules for
estimating CI for one binomial proportion using the Wilson method with MI [Lott and
Reiter, 2018] to estimate CIs for difference between two proportions. Moreover, we
developed a proper two-stage MI procedure for constructing CIs using the NW method
when the incomplete data follows a MNAR missingness mechanism. We compared the
performance of our method to NW-plug, Wald and FM methods in terms of coverage
probability and CI width using several simulation scenarios. We showed that the NW-
plug method had coverage rates below the desired rate, and lower than the other three
methods. The results for NW-MI, Wald and FM were comparable. For MCAR and
MAR, we showed that the coverage probabilities for NW-MI, Wald, and FM were at the
desired level of 95% for pC = 0.6. Moreover, for pC = 0.9, we observed that for both
MCAR and MAR, the coverage probabilities for NW-MI, Wald and FM were either
at or above 95%. Importantly, we showed the advantage of using two-stage MI over a
conventional MI in terms of the coverage rates. In terms of the average width, NW-
plug showed the shortest CIs, while the other three methods had comparable average
CI widths.
As a result of the above evaluation, NW-MI, Wald and FM are recommended over
NW-plug. Following this, we implemented NW-MI for one of the scenarios from Chapter
2 (M2 = 0.05, pCon = 0.85, n = 1071) for MNAR due to lack of efficacy in Trt. As can
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be seen in Figure 11 the results of NW-MI are now comparable with Wald and FM as
expected.
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Figure 11: Empirical type-I errors, two-stage MI strategy via MICE for MNAR due to
lack of efficacy in Trt, following NW-MI implementation
The limitation of our evaluation is that we could only assess a set of scenarios, which
although are representative of many applied research problems, do not cover all possible
scenarios. In addition, we did not assess performance of the methods presented here for
small sample sizes. The reason for that is that all the methods we used here are based on
Normal approximation, and in general are known to perform well for completely observed
data for sample sizes above 50 [Brown and Li, 2005]. Nevertheless, for smaller sample
sizes exact CI construction methods, e.g. Clopperr-Pearson [Clopper and Pearson, 1934]
could be more favorable, however the exact methods are outside of the scope of this work.
We believe that the new methods presented here could be very useful in practice.
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First of all, in many areas of applied research the outcome of interest is the difference
between two proportions. Second, many studies encounter incomplete observations and
have to make inferences given the data they observe. While it is impossible to test the
incomplete data for ignorable vs non-ignorable missingness assumption, the ignorability
assumption needs to be explicitly stated and consequently translated into a proper type
of analysis [Sidi and Harel, 2018]. The contribution of the Chapter is two-fold: first we
extend on the previous research conducted by Lott and Reiter [2018], second we propose
a relatively simple method which can be used for non-ignorable missingness.
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Chapter 4
Non-inferiority clinical trials:
treating margin as missing
information
4.1 Background
As described in Chapter 1, the choice of clinically acceptable margin (M2) continues to
be a major issue for the design and interpretation of NI trials. The fixed margin approach
described in Chapter 1 is illustrated in Figure 12. The upper part of this Figure presents
a historical comparison of the standard treatment to placebo to determine the value of
M1, which is the entire effect of the standard treatment over placebo. Following that,
M2 is chosen by clinical experts, its value is presented in the bottom part of the Figure.
It should be noted that M2 is lower than M1. In order for the new treatment to be
non-inferior, the CI in NI trial needs to be below M2. In addition, several scenarios for
the NI trial comparing the standard treatment to the new test treatment are presented
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in the bottom part of Figure 12. In those scenarios NI is concluded for the CIs with
blue point estimates, while the CI with a red point estimate corresponds to inferiority
of the new test treatment. Since different values of M2 can lead to different conclusions,
a proper determination of the clinically acceptable margin is essential for NI trials.
In this Chapter, we propose to treat M2 as missing information. We propose a survey
among clinical experts in order to determine the objective value of the margin, as well as
variability associated with it. Following our novel framework, the information obtained
from such a survey can then be combined with the NI trial results, which would lead to
an objective decision regarding the new potentially non-inferior treatment.
We mentioned in Chapter 1, that while the goal is to survey a representative sample
of clinicians, this might be hard to achieve in practice. Therefore, if clinical experts’
opinions regarding M2 are influenced by the experts’ professional or demographic char-
acteristics, surveying a small number of clinicians about M2, while obtaining general
characteristics for representative sample is sufficient when utilizing MI.
4.2 Methods
Similar to Chapters 2 and 3, Yij ∼ Bernoulli(pi) is an occurrence of a favorable event
for subject j, in a treatment group i (j = 1 . . . ni, i = Con, Trt), and pi is the true
proportion of favorable events in group i. Also, pˆCon, pˆTrt correspond to the MLEs of
pCon, pTrt respectively as defined in Chapters 2 and 3.
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Figure 12: NI clinical trial design with possible outcomes when compared to the standard
of care using fixed margin approach. The upper part of the graph presents historical
comparison of the standard of care to placebo, while the bottom graph corresponds to
the comparison of the new treatment to the standard of care in the non-inferiority trial.
NI is concluded for the CIs with blue point estimates, while the CI with a red point
estimate corresponds to inferiority of the new test treatment.
As discussed above, M2 is defined after M1’s determination, which is the previously
observed control treatment effect over placebo. Thus, M2 is commonly seen as a frac-
tion (λ) of the control treatment effect, which clinical experts consider justifiable, i.e.,
M2 = (1− λ)M1. We assume that M1 has been determined based on historical studies
and is fixed at the time the non-inferiority trial is being designed, and λ follows some
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distribution F with mean µλ and variance σ
2
λ. While for a known distribution F , any
function of random variable λ can be used to construct the null and alternative hy-
potheses to test non-inferiority, we will focus on µλ throughout this article, since the
population mean is a commonly used parameter of interest in many practical situations.
Following the notation above we can re-write the hypothesis in (2.1) as:
H0 : pCon − pTrt ≥ (1− µλ)M1 vs H1 : pCon − pTrt < (1− µλ)M1 . (4.1)
For a known population distribution F , we demonstrate how the value of the margin
could significantly impact study design in terms of sample size calculation. A sample
size per treatment arm (n) can be calculated using the following formula [Blackwelder,
1982, Dann and Koch, 2008, Julious and Owen, 2011], while assuming 1:1 allocation
ratio:
n =
(z1−α + z1−β)2(pCon(1− pCon) + pTrt(1− pTrt))
(pCon − pTrt − (1− λ)M1)2 , (4.2)
where z1−α, z1−β are 1 − α, 1 − β quantiles of standard normal distribution re-
spectively. Specifically, α, 1 − β represents desired levels of target type-I error and
power respectively. Assuming under the alternative hypothesis in (2.1) equality between
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the proportions pCon = pTrt, given the same type-I error and power, the difference be-
tween sample size calculations for some value of λ = λ∗ and µλ will be proportional
to 1
(1−λ∗)2M21 −
1
(1−µλ)2M21 . This means that, for example, if pCon = pTrt = 0.8, α =
2.5%, 1− β = 85% and µλ = 0.7, the sample size per arm using (4.2) for λ = µλ is 593,
while for λ = 0.71 it would be 634. Thus, a change of just one percent in the amount
of the original standard treatment effect to be preserved corresponds in additional 82
subjects to be recruited to an NI study.
The scenario presented here, where the F and its parameters are known is of-course
hypothetical and cannot happen in practice. We use it in order to motivate the readers
to think about the fraction of the standard treatment effect as of a random variable.
Next we discuss how F and it’s parameters could be estimated from a survey of clinical
experts.
4.2.1 Estimating fraction preservation though a survey
The distribution F and it’s parameters µλ, σ
2
λ are considered unknown and ought to be
estimated, ideally from a clinical experts survey conducted at the design stage of the
trial. We assume that in total K values of λ were collected from clinicians: λ1, . . . , λK .
Let µˆλ =
1
K
K∑
k=1
λk be MLE of µλ. Given a sufficiently large clinical experts survey,
the following approximate result holds:
µˆλ ∼ N(µλ, σ
2
λ
K
) , (4.3)
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where the variance term can be estimated by σˆ2λ =
1
K−1
K∑
k=1
(λk − µˆλ)2.
We assume further that the primary analysis of the NI trial is based on Wald’s CI as
defined in (2.2). Given a sufficiently large sample size per treatment arm, and assuming
independence between the NI trial and the clinical experts survey, one can test the
hypothesis in (4.1) at α level, by comparing the following upper (1 − α)100% CI with
zero:
pˆCon − pˆTrt − (1− µˆλ)M1 + z1−α
√
pˆCon(1− pˆCon)
nCon
+
pˆTrt(1− pˆTrt)
nTrt
+
M21 σˆ
2
λ
K
. (4.4)
If the quantity in (4.4) is smaller than zero, the null hypothesis in (4.1) will be
rejected and the new treatment will be declared non-inferior to the standard of care.
This approach is, in essence, a synthesis of the information between clinical experts
opinions and the data in a new non-inferiority trial. It corresponds to an objective
determination of a new treatment’s NI, as it takes into account opinions of the multiple
clinical experts and the variability associated with such opinions.
The apparent issue with the above approach is that, in practice, it is reasonable
to assume that K is small. Therefore the sample of the observed clinical experts re-
sponses might not be representative of the clinical experts population, and the normal
approximation in (4.3) may not hold.
Although it might be challenging to survey a large number of clinicians to obtain
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their opinion about λ, other information related to clinical experts opinions could be
more accessible (for example, number of years of treating a disease of interest or number
of patients treated), and will be determined as X for the rest of this Chapter. In
general, X can be a vector, here for simplicity we will assume that it contains only one
random variable. As a result we have a dataset which contains a fully observed X and a
partially observed λ. This resembles a missing data problem, which is discussed in the
next section.
4.2.2 Treating fraction preservation as missing data
Although observing all the values of λ from a representative experts sample would be
extremely helpful and will allow a proper use of (4.3), such observation is unlikely to
happen in practice. As a result, we propose to treat unobserved values of λ as missing
information. Given additional variable X, which is observed for all the experts from a
representative sample, we can use MI procedure to properly estimate µλ and σλ, which
can then be used in (4.4).
For MI purposes, we define a quantity of interest Qλ = µλ. Similar to the representa-
tion in (2.16), we assume that for completely observed values of λ, (Qλ−Qˆλ) ∼ N(0, Uλ),
where Qˆλ is an estimate of Qλ and Uλ is a variance of (Qλ − Qˆλ). Using a maximum
likelihood approach, we have: Qˆλ = µˆλ and Uλ =
σˆ2λ
K
.
Since it was assumed that demographic and professional characteristics of clinicians
affect their opinion about M2, we used completely observed values of X to multiply
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impute the incomplete data. The MI was utilized through classification and regression
trees (CART) imputation method [Burgette and Reiter, 2010]. CART is a nonparamet-
ric MI approach, where a conditional distribution of a variable is estimated from multiple
predictors by forming homogeneous subsets of a predictor space. CART was chosen over
a Bayesian linear regression imputation model [Rubin, 2004] due to its tendency to pro-
duce small mean squared errors [Akande et al., 2017]. As in Chapter 2, the imputations
were produced L times using MICE. The L pairs of estimates (Qˆ
(l)
λ , U
(l)
λ ), (l = 1, . . . , L)
are then combined following the procedure outlined in (2.17)- (2.21). As a result, we
have (Qλ − Q¯λ)/
√
Tλ ∼ tνλ, where νλ has a similar form as ν in (2.21).
If the subject-level data is fully observed, the µˆλ and
σˆ2λ
K
in (4.4) are then replaced
with Q¯λ and Tλ respectively. In addition the z1−α in (4.4) is replaced with an appro-
priate cut-off value from a sum of normal and Student’s t-distribution using general
purpose convolution algorithm with Fast Fourier Transformation (FFT) [Kohl et al.,
2005, Ruckdeschel et al., 2006].
In case the subject-level data are incomplete, a separate MI procedure should be
applied for that data. For simplicity we assume that the incomplete data follow ignorable
missingness. Now, we define an additional quantity of interest QY = pCon−pTrt, so that
for completely observed data (QY − QˆY ) ∼ N(0, UY ), where QˆY = pˆCon − pˆTrt and
UY = UCon − UTrt with Ui = pˆi(1−pˆi)ni . Using a logistic regression model with MICE, and
observed covariates, the incomplete data is imputed D times. Similar to the margin
imputation described above, we will end up with D pairs of estimates (Qˆ
(d)
Y , U
(d)
Y ), (d =
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1, . . . , D), which can then be used in the procedure outlined in (2.17)- (2.21). As a result
we have: (QY − Q¯Y )/
√
TY ∼ tνY , where νY has a similar form as νλ above. Following
that, in addition to replacing µˆλ and
σˆ2λ
K
with Q¯λ and Tλ in (4.4) respectively, we will also
replace the pˆCon−pˆTrt and pˆCon(1−pˆCon)nCon +
pˆTrt(1−pˆTrt)
nTrt
in (4.4) with Q¯Y and TY respectively.
Also the z1−α is replaced with an appropriate cut-off value from a sum of two Student’s
t distribution using the FFT algorithm.
4.2.3 Rates of missing information
Schafer [1997] recommends calculating the rates of missing information, pointing out
that such quantities could be useful when evaluating the effect of the incomplete data
on the inferential uncertainty of the parameter of interest. In our case, the missingness
is due to unobserved clinical experts opinions regarding λ, as well as due to unobserved
subject-level data when the patient data are incomplete.
We estimated rates of missing information due to unobserved λ as: γλ =
Bλ
Bλ+U¯λ
,
and rates of missing information due to unobserved subject-level data as γY =
BY
BY +U¯Y
[Harel, 2007]. Since, we assume that the two data sources are independent, and the MI
is done for each dataset separately, rather than conditionally, the total rate of missing
information was defined as γ = γλ + γY .
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4.2.4 Simulations details
Subject level information is fully observed
Suppose the overall population of physicians consists out of 1000 medical doctors (MDs),
who treat a specific condition. Further, we assume that 300 of these MDs, who are
representative of the overall population come to a clinical conference (K = 300), and
it is feasible for us to survey only 3% of them (9 MDs). Also, we assume that years of
experience treating the condition is known for all the MDs, who come to the conference.
Following the above notation, λk is a fraction preservation of the control treatment
effect over placebo for kth clinical expert, also let Xk be a number of years that clinical
expert has been treating a condition of interest. Without loss of generality we will drop
the index k from the following explanation. Assume that for any (λ,X) ∼ N2(µλ =
0.7, µX = 20, σλ = 0.12, σX = 7, ρ), where ρ ∈ (0.4, 0.7). The positive correlation
between X and λ indicates that more experienced clinical experts are prone to be more
conservative with respect to the clinical margin choice. For brevity, and due to similarity
between the results, we only present results for ρ = 0.4 in this Chapter, while the results
for ρ = 0.7 appear in Appendix C. Let Rλk be and indicator variable for whether λk
was observed (Rλk = 1 means that clinician k did not participate in the survey). Two
scenarios of participation were considered: i) more experienced clinicians are more likely
to participate in the survey; and ii) a random sample from the K clinicians above. For
the first scenario, the observed/unobserved values of λ were assigned using P (Rλk =
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1|X > 20) = 0.95 and P (Rλk = 1|X ≤ 20) = 0.99, while for the second scenario
P (Rλk = 1|X > 20) = P (Rλk = 1|X ≤ 20) = 0.97.
The value of M1 was set to be 0.23 which was assumed to be known from a meta-
analysis of the relevant historical trials. In addition, the subject-level data was gener-
ated using a combination of pCon = 0.8, pTrt ∈ (0.775, 0.8, 0.825) and nCon = nTrt ∈
(250, 500), which resulted in a total of 6 scenarios. The values considered for the sim-
ulation are partially based on completed NI trials [Eriksson et al., 2007, 2011]. Each
scenario was simulated 5000 times, i.e. both MDs population sample and NI trial data
were simulated 5000 times. It should be noted that higher number of simulations did
not alter the results.
As stated previously, non-inferiority of the new treatment was determined using the
confidence interval in (4.4). The NI decision was considered objective (OBJ) if it was
based on the representative sample of MDs (300 MDs). Other methods used for an NI
decision were: MI of the margin as described in the previous section with X and L = 20,
using only observed λ values from the survey (OBS) (only 9 MDs), as well as minimum
and maximum values of λ from the representative sample of the K clinicians (MIN and
MAX respectively) (one MD each). Minimum and maximum values were considered in
order to demonstrate how the NI decision could be affected by consulting only one MD
during the conference, who happens to be the least or the most conservative clinician in
that conference.
The performance of these methods was assessed by comparing the rates of the NI
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decision to the OBJ decision rate. A decision rate was calculated as a proportions of
times NI was inferred out of the 5000 simulations. The most favorable approach is the
approach for which the NI decision rate is the closet to the OBJ NI decision.
Subject level information is incomplete
After comparing NI decision rates as described in the previous section, where the subject-
level information was considered completely observed, we turn to evaluation of NI deci-
sion rates when such information is incomplete. For the purposes of this evaluation, we
only used survey data where the more experienced MDs were more likely to participate
in the survey, a situation that is likely to appear in practice. The incomplete primary
outcome data was assumed to follow ignorable missingness, including MCAR and MAR.
In order to impose both MCAR and MAR processes, a variable Z was added to the
NI trial simulation. Z was set to have higher values for control treatment group and have
higher values for subjects experiencing an event of interest in both groups. Specifically,
Z|Con, Y = 1 ∼ N(180, 20), Z|Con, Y = 0 ∼ N(100, 20), Z|Trt, Y = 1 ∼ N(130, 20),
Z|Trt, Y = 0 ∼ N(80, 20). Z could be seen as a patient reported outcome (PRO)
measured during the study, and is positively correlated with the outcome of interest.
Let RSij be and indicator variable for whether Yij was observed (RSij = 1 means that
outcome Yij was unobserved for patient j in treatment i). The following logistic function
was used to determine observed/unobserved values of Y in each treatment group:
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P (RSij = 1) =
1
1 + exp(−θ0 − θ1iZij) , (4.5)
where θ0 = log(
DO
1−DO ) − θ1iZ¯i, Z¯i =
ni∑
j=1
Zij, θ1i represents the effect of Z in group i
on the missingness, and DO stands for the overall drop-out rate, which was assumed
to be the same in both treatment groups and was set to 20% as a reasonable upper
bound for NI trials that encounter some level of missingness [Rabe et al., 2018]. The
following two sets of values were considered for θ1i: θ1,Con = θ1,T rt = 0, which means
that the PRO measure Z didn’t affect the drop-out of patient j in treatment group i,
and θ1,Con = −0.009, θ1Trt = 0.013, which means that patients with lower values in Z
were more likely to drop out in the control group, whereas the opposite effect was set in
the new treatment group. As a result, the first set of the values for θ1i specified above
constituted to MCAR process, while the latter represent an MAR process. Following
that, the difference between the two proportion pCon−pTrt, was unbiased when estimated
from the complete cases under MCAR, and biased under MAR with observed difference
being more profound than it actually is.
The incomplete subject-level data was multiply imputed D = 20 times as described
in Section 4.2.2, and consequently used for NI decision based on MI approach. For
OBS/MIN/MAX approaches, the complete cases from the NI trial were used. Similar
to Section 4.2.4, the performance of the methods was assessed by comparing the rates
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of the NI decision to the OBJ decision rate.
4.3 Results
Figures 13, and 14 demonstrate differences between OBJ NI trial decision and the other
four methods under consideration, based on the proportion of the simulated studies that
conclude NI when the subject-level data are completely observed. The results in these
Figures are presented in terms of the deviation from the OBJ decision. Therefore, the
method closest to 0 is considered to be the most favorable. The difference between the
Figures is that in Figure 13 MDs who participate in the survey are more likely to be
more experienced than MDs who do not participate in the survey, while in Figure 14 that
sample is random. As shown in Figures 13-14, the MI approach for NI decision was shown
to be the closest to the OBJ decision in most of the scenarios, with deviations between
0.14% and 4.8%. In general, the OBS approach was the second closet to the OBJ, with
deviations of between 5.8% and 24%. This was followed by the MIN, which resulted in
deviations between 3.4% and 65%. The MAX resulted in the highest deviations, that
ranged between 22% and 71%.
Figure 15 has a similar presentation as Figure 13 described above, it demonstrates
results for partially observed subject-level data with the MCAR assumption. As shown
in Figure 15, the MI-based decision was the closest to the OBJ decision in most of
the scenarios, and deviated by 2% to 7.2% from the OBJ rates. In the case where
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Figure 13: Deviation from objective NI decision, when more experienced MDs are more
likely to participate in the survey, subject-level data are fully observed.
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Figure 14: Deviation from objective NI decision, when MDs participation in the survey
is completely random, subject-level data are fully observed.
pT = 0.825, n = 500, the MIN approach performed similar to MI. To explain this result,
we present the NI decision rates (rather than deviations from OBJ) in Table 7. As
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show in Table 7, the decision rate for MIN was 100%, which means that all of the 5000
simulated studies concluded NI of the new treatment. This result is not surprising, since,
in this case, the new treatment is actually superior by 2.5% to a standard treatment,
which means that it would be easier to claim NI. Moreover, the MIN approach represents
the least conservative view of the margin, which again would make an NI claim easier
to make. For the rest of the scenarios, MIN had over 20% deviation from OBJ decision
rates. OBS decision rates deviated between 11% and 31%, while MAX deviation ranged
between 22% and 72%.
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Figure 15: Deviation from population based non-inferiority decision, subject-level data
are MCAR.
Figure 16 has a similar presentation as Figure 13 described above, it reveals results
for partially observed subject-level data with the MAR assumption. As shown in Figure
16, MI decision approach performed overwhelmingly better than the OBS and the MAX
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Table 7: Percent of studies concluding NI by method, when more experienced MDs are
more likely to participate in the survey, subject-level data are MCAR.
pTrt n OBJ MI OBS MIN MAX
0.775 250 22.6 20.6 12.1 78.5 1.1
0.775 500 39.4 35.7 17.2 97.5 0.9
0.800 250 49.1 43.5 29.0 92.6 4.8
0.800 500 77.7 70.5 46.4 99.8 6.1
0.825 250 76.9 70.3 53.4 98.7 15.1
0.825 500 96.6 93.0 77.9 100.0 26.5
approaches. Moreover, the deviations from the OBJ decision rates increased dramatically
for OBS and MAX. This is reasonable, since the apparent difference in proportions for
MAR is larger than it really is, which means that it is harder to claim NI. The MIN
approach, however showed similar results to MI for pTrt = 0.825 scenarios, as well as
pTrt = 0.8, n = 250.
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Figure 16: Deviation from population based non-inferiority decision, subject-level data
are MAR.
The rates of missing information due to unobserved λ were between 30% and 35%
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for both ρ ∈ (0.4, 0.7) when more experienced MDs were more likely to participate
in a survey, and between 27% and 33% when the survey participation was completely
random. It should be noted that, as expected, in both cases higher rates of missing
information were observed for ρ = 0.4. For the incomplete subject-level data, the rates
of missing information due to unobserved patient data ranged between 5% and 6% for
both MCAR and MAR. As a result, the total rates of missing information were between
35% and 40%. As can be seen, the main contributor to the overall rates of missing
information is unobserved clinical experts opinions.
4.4 Conclusion
With NI trial design being more frequently used in recent years, it is imperative to
address concerns raised by several systematic reviews of such trials [Wangge et al.,
2010, Schiller et al., 2012, Rehal et al., 2016, Althunian et al., 2017, Rabe et al., 2018].
Specifically, one of the major issues that was raised is the apparent lack of justification
for the clinically acceptable margin. The choice of such a margin is critical as it directly
affects the design stage of an NI study, i.e., the anticipated sample size, as well as further
interpretation of the results once the study is complete. Even if, other common issues
related to the NI design, such as availability of the historical data and the consistency
of standard treatment effect over placebo are resolved, it is still not clear how to choose
a clinically acceptable margin.
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In this Chapter we present a novel framework, in which we propose to treat the mar-
gin as missing information and estimate it through clinical experts survey. Using such
framework would allow objective estimation of clinical margin and provide justification
for its choice. Furthermore, within this framework we have evaluated the performance
of several methods while comparing the rates of NI decisions to the proportions of ob-
jective NI determination. Overall, we found that, out of the four approaches considered,
decision rates using MI was generally the closest to the objective decision rates. Al-
though, the least conservative margin approach had similar results to MI in several
cases, in general, it had high deviations from the OBJ in most of the scenarios. Also,
the most conservative choice of clinically acceptable margin deviated significantly from
the objective decision rates. Both the most and the least conservative margin choices
show the implication and risk of consulting with only one clinical expert, who might
have extreme views regarding such a choice. Thus, the determination of the clinically
acceptable margin should not be done using an opinion of one clinical expert.
In addition to CART MI, we have also looked at the performance of a more com-
monly used Bayesian linear regression MI procedure. This method resulted in higher
between-imputation variance than CART MI, which is not surprising due to the small
number of MDs participating in the survey. As a result, the rate of the simulated studies
concluding NI using Bayesian linear regression MI procedure was much further than OBJ
decision compared to CART MI. Following that, given the potentially small sample size
of the clinical experts survey, we recommend using a CART MI procedure to minimize
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subjectivity of the NI decision.
The rates of missing information due to the unobserved clinical experts opinions was
the main contributor to the overall rates of missing information. This result underlines
the importance of taking into account uncertainty associated with the choice of margin,
when it is observed for a small fraction of clinical experts. In addition, it has impli-
cations for the study design stage, when the allocation of the study-specific funds is
discussed. Following our results, given a limited study budget, an entity running the
study might consider allocating a considerable amount of study funds toward the design
stage, including margin determination through a clinical experts survey.
We would also like to point out several limitations of this work. First, we only con-
sidered a limited number of scenarios. If investigators have a specific scenario in mind
which differs from the ones presented here, they should assess it using the framework
outline. Second, the framework presented here is new and has not been applied pre-
viously, therefore we cannot comment on possible logistic issues that might arise from
such data collection besides the ones specified within the framework.
Given the ongoing challenges with respect to NI margin choice and justification, there
is a need for a new, more evidence-based, and transparent approach, which takes into
considerations variability in clinical experts opinions about such choice. The margin
choice has direct implication on the non-inferiority decision, which is important for both
drug approval and the public health policy process. However, an approach which allows
an objective choice of margin have not been developed prior to this work. Therefore,
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the contribution of this Chapter is the novel framework, which accounts for uncertainty
associated with non-inferiority margin choice and thus minimizes subjectivity of such
choice. Use of this framework will allow an empirical justification of margin choice, and
therefore help resolve current practical issues related to it.
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Chapter 5
Comprehensive benefit-risk of
non-inferior treatments using
multi-criteria decision analysis
5.1 Background
As stated in Chapter 1, a non-inferior treatment needs to show some benefit over stan-
dard one in order to outweigh decreased effectiveness. As discussed in Chapter 1, several
outcomes may be considered when assessing the overall benefit-risk (BR) of the new non-
inferior treatment. Various methods exist for structured BR assessment. We chose to
use multi-criteria decision analysis (MCDA) due to the reasons mentioned in Chapter 1.
One of the MCDA’s critiques has been it’s deterministic form, which does not take into
account variability of either criteria values, or preference weights. To overcome these
issues, Tervonen et al. [2011] proposed a stochastic multicriteria acceptability analysis
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(SMAA), that also allows BR assessment without explicit weight elicitation from deci-
sion makers. Wen et al. [2014] presented two approaches to incorporate clinical data
uncertainty into MCDA for BR assessement. Waddingham et al. [2016] presented a
Bayesian MCDA model, where outcomes uncertainty was taken into account. Wang
et al. [2016] proposed a simpler approach to SMAA, using discriminatory probabilities,
which allow comparison between treatments performance for unobserved or partially
observed weights. Saint-Hilary et al. [2017] presented an approach that unifies MCDA
and SMAA through the use of Direchlet prior.
While the above approaches made a substantial contribution to the structural BR
assessment toolkit, these were mainly based on aggregated clinical trial and preference
data. In the presence of individual patient-level data, such approaches may be subopti-
mal since benefits and harm experienced by patients could vary from patient to patient
[Evans and Follmann, 2016]. Li et al. [2019] were the first to develop an approach that
takes into account heterogeneous responses of the patients to the treatments, as well as
consider individual preferences. These authors used a Bayesian multicriteria decision
method; an extension of the original SMAA with latent trait models. The main draw-
back of this approach, however, is its complexity, as well as the lack of clarity how the
patient preference weights should be obtained.
The purpose of this work is to develop a simple MCDA approach for structured BR
assessment of the new non-inferior treatment when compared to the standard of care us-
ing patient-level data from an NI study. With the growing recognition of the importance
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of preference elicitation by the patients [Marsh et al., 2017, FDA, 2018], we propose to
carry out such elicitation at the beginning of NI trials. Since patient demographic char-
acteristics and baseline (BL) disease status are likely to influence patient outcomes, as
well as patient preferences, we believe that it would be beneficial to study these within
the same trial. Also, since the introduction of any additional questionnaire is likely to
increase burden of the study participants, and investigators, as well as, on the sponsor
conducting the study, we suggest gathering preference information only from a random
sample of the trial patients, while using MI analysis to create an overall BR assessment.
5.2 Methods
5.2.1 MCDA patient-level indices
Let MCDAij be MCDA index for patient j (j = 1, . . . , ni, where ni is number of
patients assigned to treatment i) assigned to treatment i (i = Con, T tr). Also let uijc,
and wijc be a scored outcome/criteria and a preference weight respectively for patient j,
for criteria c (c = 1, . . . , C), in treatment group i. We assume that the scored outcomes
are calculated using a linear partial value function, which was previously used by several
authors [Tervonen et al., 2011, Waddingham et al., 2016, Li et al., 2019]. If ξijc is
an outcome value for patient j, for outcome c, in treatment i, and ξ′c, and ξ
′′
c are the
highest and the lowest value to be considered in preference elicitation for outcome c, then
uijc =
ξijc−ξ′′c
ξ′c−ξ′′c when higher values are considered as more beneficial, and uijc =
ξ′j−ξijc
ξ′j−ξ′′j
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when higher values are considered as more harmful. As a result, all the score values
should range between 0 and 1, so that 1 represents the best state and 0 the worst state
for a given criteria.
Weight elicitation is assumed to be done using “swing weighting” [Mussen et al.,
2007, Marsh et al., 2016]. In a “swing weighting” approach, a subject is required to first
determine which criteria’s “swing ” is the most important to them, and assign 100%
to that criteria. “Swing” corresponds to a change from the worst to the best state, for
instance, a change from having pain to no pain. Then, the subject needs to provide
relative weights to the rest of the considered criteria using “swings” in those criteria.
For example, if only treatment response and adverse event (AE) are considered for BR
assessment, and a subject identified treatment response as 100%, while AE occurrence
as 50%, this means that, for this subject AE occurrence is only half as important as
responding to the treatment. It should be noted that in this example, a “swing” in
treatment response criteria means experiencing treatment response, while a “swing” in
AE criteria means occurrence of AE. After subject-specific weights are obtained, the
weights are normalized before they can be used in MCDA calculation.
Following the above, MCDA indices are calculated using:
MCDAij =
C∑
c=1
uijc(wijc/
C∑
c=1
wijc) . (5.1)
An MCDA index for a specific patient represents an overall score for BR trade-off
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using the patient’s personal preferences. Higher indices contribute to a more favor-
able BR assessment. Therefore, in order to evaluate overall benefit of a non-inferior
treatment, we can compare the MCDA indices between the treatment groups. Since,
in drug development, it is not uncommon to compare population means, we chose to
use the estimated MCDA means in order to claim whether on average the BR of the
new treatment is superior to the available therapy. Due the fact that MCDA indices
are constructed using a linear combination of random variables that may have different
distributions, it is hard to make a distributional assumption about them. Given the
goal of between-group mean comparison, and the central limit theorem (CLT), we chose
to make this comparison by constructing 95% CI for mean differences (control vs new
treatment) with unequal variances (Welch’s T-test). If the upper bound is below zero,
then the new treatment would be considered overall more beneficial than the standard
treatment. It should be noted that there has been increasing research into the advan-
tages of the simple Welch’s T-test over the Wilcoxon-Mann-Whitney test [Skovlund and
Fenstad, 2001, Fagerland and Sandvik, 2009, Fagerland, 2012].
5.2.2 MCDA of a random sample of a clinical trial participants
While, ideally, we would like to obtain patient preferences from all trial participants,
collecting such additional information might not be feasible as it introduces further
burden on patients, investigators and sponsors. We propose to collect patient preferences
from only a random sample of the trial participants at the beginning of a trial and use
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an MI approach to restore the preferences of all the trial participants. Following that,
we assume ignorable missingness throughout this Chapter.
5.2.3 MI for patient preferences
As described above, patient preferences are considered to be obtained using “swinging
weighting”, which means that the weights could range between 0 and 100. While it
is reasonable to require that an imputation procedure produces only values within the
plausible range, the ultimate goal of MI is to efficiently estimate a parameter of interest.
Therefore, it is not necessary to multiply impute values within a specified range. In
fact, Rodwell et al. [2014] performed a simulation study, where different MI approaches
were implemented for bounded incomplete variables. Specifically the authors evaluated:
the commonly used Bayesian linear regression with no truncation, post-imputation pro-
cessing (i.e. assign min/max if the imputed values falls outside the plausible range),
truncated regression and predictive mean matching. The authors concluded that, in
terms of bias of the point estimate, variance and coverage, the usual regression with no
truncation performed better than the other methods.
Given a variety of MI methods [Harel and Zhou, 2007], and results from Rodwell et al.
[2014] we decided to use Bayesian linear regression (NORM). Due to its simplicity, we
also evaluated Bayesian linear regression with post-processing (NORM TRUNCATED).
In addition, we assessed CART MI [Burgette and Reiter, 2010]. We chose to use CART
due to its ability to capture complex data structures [Burgette and Reiter, 2010], which
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might arise from patient preference elicitation. In addition, it should be noted, that
CART returns imputed values which are within the range of the observed values, there-
fore the weights range of 0 to 100 is satisfied.
Similar to the representation in (2.16), we assume that (Q − Qˆ ∼ N(0, U), where
Q is the mean difference in MCDA indices between the standard and new non-inferior
treatment. Specifically, in our case Qˆ = MCDACon −MCDATrt, where MCDAi =
1
ni
ni∑
j=1
MCDAij. Also, U =
S2MCDACon
nCon
+
S2MCDATrt
nTrt
, where S2MCDAi =
1
ni−1
ni∑
j=1
(MCDAij −
MCDAi)
2. Further, we assume that patient preferences are imputed L times, and within
each lth imputed dataset (l = 1, . . . , L) we obtain pairs of summaries defined above
(Qˆ(l), U (l)). Using Rubin’s combination rules Rubin [2004] as described in Chapter 2,
the L pairs of estimates are then combined following the procedure outlined in (2.17)-
(2.21). As a result, we have (Q− Q¯)/√T ∼ tν , where ν has a similar form as ν in (2.21).
5.2.4 Simulation
Simulation set-up for clinical trial data
Simulation set-up is based on the information from recently published results of NI
HAWK study Dugel et al. [2019]. HAWK was one of the two NI pivotal studies, that
showed the NI of Brolucizumab 6mg when compared to Aflibercept 2mg for treatment
of neovascular age-related macular degeneration. The planned sample size for this study
was 297 patients per treatment arm, therefore we used 300 patients per arm for simplicity
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in our simulations.
We simulated the following efficacy outcomes for primary and a key secondary end-
point: best corrected visual acuity (BCVA) change from BL to week 48, and central
subfield thickness (CST) change from BL to week 16. It should be noted that, while
higher values of BCVA correspond to a better health, the opposite is true for CST. In
addition, we simulated the following safety variables, which were presented by Dugel
et al. [2019]: non-ocular adverse events (AEs), and ocular AEs.
According to Dugel et al. [2019], the analysis of primary endpoint was adjusted for
age and BCVA at BL, thus the primary endpoint (PE) outcome was generated as a
linear function of these two BL measures. The statistical analysis methods for the key
secondary endpoints (SEs) were not specified by the authors. Therefore, similar to the
primary outcome, the SE was generated as a linear function of age and CST value at
BL. For simulation purposes, it was assumed that all the outcome measures are more
likely to worsen for elder patients, as well as unfavorable events are more likely to appear
in elder patients. In addition, for efficacy variables, we assumed that patients who are
sicker at BL would have lower rates of disease worsening than patients who are healthier
at BL. Also, we assumed that patients with lower BCVA are more likely to experience
ocular AEs.
The simulated BL values included: BCVA, CST, subretinal fluid (SRF), intrareti-
nal fluid (IRF), sub presence of retinal pigment epithelium (sub-RPE), age and gender.
SRF, IRF and sub-RPE BL variables were added, because these were used in other key
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SEs, and thus should be considered as important. The BL variables were generated
using a multivariate normal distribution, with a vector of mean and standard deviation
values as reported in [Dugel et al., 2019], for binary variables the reported proportion of
events (p) was used as mean and
√
p(1− p)/n, where n is a sample size was used as stan-
dard deviation. Since the vision-related measures deteriorate with age, positive pairwise
correlations were assumed between age, and CST, SRF, IRF, sub-RPE, whereas nega-
tive pairwise correlation was assumed between age and BCVA. Also, negative pairwise
correlations between BCVA and CST/SRF/IRF/sub-RPE were assumed, while positive
pairwise correlations between CST and SRF/IRF/sub-RPE were set. For simplicity it
was assumed, that SRF, IRF and sub-RPE had zero pairwise correlations, and gender
was assumed uncorrelated with other variables.
Simulation set-up for patient weights
To assess the overall benefit of the new non-inferior treatment to a standard treatment,
preference weights were assigned using patients BL characteristics. Also continuous BL
characteristics (BCVA and CST) were categorized using cut-off values reported in [Dugel
et al., 2019]. The weights were generated using the following three scenarios:
1. In Scenario 1, we used three criteria: BCVA change from BL to week 48 (primary
endpoint (PE)), ocular and non-ocular AEs. It was assumed that, on average,
patients care more about non-ocular AEs than PE or ocular AEs. Preference
weights for PE were defined as a function of BCVA at BL as follows: mean weight
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of (70, 50, 30) were assigned to patients with lower, medium and high values of
BCVA at BL respectively. This indicates that a patient with worse vision status
at BL will be more likely to assign higher weights for improvement of the vision
status, than one with a better vision at BL. For ocular AEs, the mean weights of
(50, 80) were assigned for female and male patients respectively. For non-ocular
AEs, the mean weights of (70, 90) were assigned for female and male patients
respectively. Higher weights for AEs for male patients indicate that men care
more about experiencing AEs than women.
2. In Scenario 2, we used four criteria: PE, ocular AEs, non-ocular AEs, and CST
change from BL to week 16. In this scenario, patients on average care more about
PE, than the other three endpoints. The mean weights for PE were assigned as
(90, 60, 30) for low, medium and high values of BCVA at BL respectively. The
mean weights for ocular AEs, and non-ocular AEs were set to (50, 70) for female
and male patients respectively. Also, the weights for CST endpoint were defined
mean values of (30, 45) for patients with low and high CST at BL respectively.
This indicates that patients with low CST care less about changes in this outcome.
3. In Scenario 3, we used the same criteria as in Scenario 2 above. The weights for PE
were defined in the same way as in Scenario 2. For ocular AEs, the mean weights
of (70, 80) were assigned for female and male patients respectively, while the mean
weights of (30, 40) for females and male patients were assigned respectively for
98
non-ocular AEs. For CST, the mean weights of (15, 30) were assigned for patients
with low and high CST at BL respectively. In this scenario, patients, on average,
care more about PE, and ocular AEs than non-ocular AEs and changes in CST.
We compared MCDA indices for all the enrolled patients, then we randomly masked
between 50% to 90% of the patients preference, and consequently MCDA indices (em-
ploying MCAR missingness structure) overall and made the same comparison using
CCA or MI. The idea here was to see whether MI would be as good as using all study
participants, so that performing preference elicitation as an ancillary study within an
NI study is advantageous. In addition, for Scenario 3, we have also evaluated masking
between 50% to 90% of patients preferences based on patients’ CST scores at BL (em-
ploying MAR missingness structure) so that patients with low CST at BL have higher
probability of being unobserved than patients with high CST at BL.
Patient weights were imputed using all available BL characteristics. It should be
noted that BCVA and CST at BL were used in their continuous form. Similar to the
previous chapters, all the MI methods were implemented using MICE. The number of
simulations was 1000, the number of imputations was 10, and CART MI was set for
a minimum of 10 leaves per split. It should be noted that increasing the number of
simulations or imputations, as well as decreasing the number of leaves per split, did not
alter the inferences.
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5.3 Results
Results of a single simulated study are presented in Figure 17. Each column of the graph
corresponds to a different criteria/outcome, with the top part of the column showing
descriptive statistics of the criteria at the end of the trial by treatment group, and the
bottom part of the column showing the distribution of the weights associated with that
criteria and assigned by the patients at BL. In addition, different colors on the bottom
part of each column correspond to the BL characteristics that affect patients’ preferences.
For example, the first column in Figure 17 corresponds to BCVA change from BL criteria
(which is the PE), the top part of the graph shows boxplot for PE by treatment. As
can be seen there is no difference between the treatments in terms of BCVA, which is in
accordance with the results reported in [Dugel et al., 2019]. The bottom part of the graph
shows the distribution of the weights assigned for the PE by the patients based on BCVA
at BL status (status can be low, medium or high, which mean severe, moderate and mild
vision impairment respectively). As specified above, we assume that patients with worse
vision at BL are more likely to assign higher weights for vision improvement. And this
is what is seen in the bottom part of the graph, i.e., patients with “low” (red) BCVA
at BL have higher weight values, while patients with “med” (green) and “high” BCVA
at BL assign lower weights. The second and third columns of Figure 17 correspond to
similar representation of ocular and non-ocular AEs, whereas the preferences for both
are affected by gender as specified in the previous Section. Overall, Figure 17 shows that
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the new treatment seems to be better than the control in non-ocular AEs, this criteria
also has higher weights than the other two. Following that, the new treatment might
have only a slightly better BR profile than the control overall.
Figure 18 presents results from the 1000 simulated studies, and percent of the time
the new non-inferior treatment was declared as favorable when compared to control using
the three outcomes as specified in Scenario 1 and their corresponding weights assigned
by the patients. The dashed line in the Figure represents a result when the weights
are obtained for all the study participants, while the columns show results produced by
the methods under evaluation when only using a sample of the trial participants. As
can be seen in Figure 18, the MI results are close to the fully observed weights, while
CCA results are not. For example, when only 10% of the trial participants provide their
preferences, then CCA will declare a new non-inferior treatment as favorable only 5.1% of
the time, while CART MI, NORM MI, and NORM TRUNCATED MI will do so 17.4%,
17.9%, and 16.2% of the times respectively. Given the fact that 17.6% correspond to
the fully observed weights (dashed line), the MI methods demonstrate favorable results.
Figure 19 has a similar presentation as Figure 17, and shows results of a single study
for Scenario 2. As shown in Figure 19, the patients care more about PE than the other
three outcomes. However given favorable results in CST outcome and non-ocular AEs,
there is a good chance that the new treatment has a better BR profile than a control.
This is demonstrated in Figure 20, which has a similar presentation as Figure 18, here
the % of the studies with a favorable BR for the new treatment is 93.1%. Also, the MI
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Figure 17: Outcome criteria values per treatment group (upper plots) and weights dis-
tribution (lower plots). Single study results. Scenario 1.
results are close to the fully observed weights, which is not the case for CCA. There is
also a minimal difference between the MI methods.
Figure 21 has a similar presentation as Figure 17, and shows results of a single study
for Scenario 3. As shown in Figure 21, the preferences for the change in CST, the
outcome that shows a clear advantage of the new treatment over the control, are lower
than in Scenario 2 (Figure 19). As a result, it is expected that the overall BR profile is
now worse than in Scenario 2 (Figure 20), which is shown in Figure 22. The % of the
studies with a favorable BR of the new treatment is now 32.1%. The results of MI and
CCA are consistent with the previous two scenarios.
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Figure 18: % of trials with beneficial BR profile for a new treatment. Scenario 1. The
dashed line represents a result when the preference weights are observed for all study
participants.
Figure 23 has similar presentation as Figure 18, and shows percent of the times the
new non-inferior treatment is declared as beneficial compared to the control, when MAR
structure is imposed in Scenario 3. As can be seen in Figure 23, the results from MI
were still favorable, with minimal differences between the imputation methods.
5.4 Discussion
In this Chapter, we present a novel approach for comprehensive BR assessment of new
non-inferior treatments which allows researchers to elicit patient preferences from an NI
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Figure 19: Outcome criteria values per treatment group (upper plots) and weights dis-
tribution (lower plots). Single study results. Scenario 2.
study. Similar to the original MCDA, our approach allows one to incorporate multiple
outcomes into BR assessment. The advantage of our approach over the original MCDA,
is that it also allows one to incorporate variability associated with both outcomes values
and patient preferences. In order to minimize a participation burden for patients and
medical monitors, as well as a financial burden for a sponsor due the collection of the
preference data, we propose collecting such data only for a sample of trial participants.
If such a sample is random, then as we showed, MI results are very close to the results
based on all trial participants preferences.
While our simulations were mainly based on MCAR, we also showed favorable results
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Figure 20: % of trials with beneficial BR profile for a new treatment. Scenario 2. The
dashed line represents a result when the preference weights are observed for all study
participants.
of MI under MAR. It should be noted, that although MCAR is unlikely to hold in
clinical trials [Little et al., 2012], this missingness structure could be embedded in a
study design. In other words, one could design a study where the participants of the
ancillary preference survey are randomly chosen. If the preferences are influenced by
patients’ BL characteristics, a plausibility of MCAR can be evaluated by comparing
these characteristics between ancillary study participants and non-participants.
The consideration of MCDA scores’ variability in BR assessment irrespective of a trial
design has been recently evaluated by Wen et al. [2014] and by Broekhuizen et al. [2017].
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Figure 21: Outcome criteria values per treatment group (upper plots) and weights dis-
tribution (lower plots). Single study results. Scenario 3.
Wen et al. [2014] proposed two methods that take into account clinical data variability,
including a simulation method. Although the authors focused on the aggregated clinical
trial data, they outlined a bootstrap procedure which could be used in cases when
patient-level data are available. It should be noted that patients preferences in this
approach are fixed. We implemented the bootstrap procedure as proposed by Wen et al.
[2014], while using fixed weights in Scenario 3 from Section 5.2. The fixed weights were
calculated as weighted average of the mean preferences specified for Scenario 3 based on
the relevant BL characteristics. For example, since the mean weights for the PE were
(90, 60, 30) for low, medium and high values of BCVA at BL respectively, and given for
106
0%
10%
20%
30%
10% 20% 30% 40% 50%
% of patients with observed preferences
%
 o
f t
ria
ls
 w
ith
 b
en
ef
ici
al
 B
R 
fo
r 
Tr
t v
s 
Co
n
Method CART NORM NORM TRUNCATED CCA
Figure 22: % of trials with beneficial BR profile for a new treatment. Scenario 3. The
dashed line represents a result when the preference weights are observed for all study
participants.
example, proportion of patients who have such BCVA values at BL is 20%, 50% and 30%
respectively, the fixed weight for that PE for all the patients would be 84. The use of
one fixed weight for all the patients, rather then individual patient preferences resulted
in 52.9% of the simulated studies concluding favorable BR of a non-inferior treatment
over a standard one. This is 20% more optimistic than the original 32.1% (dashed line
in Figure 22), when each patient provided his/her preference.
Broekhuizen et al. [2017] suggested a probabilistic approach, where uncertainty in
weight preferences identified by the patients in the previous preference survey studies,
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Figure 23: % of trials with beneficial BR profile for a new treatment. Scenario 3 with
MAR missingness structure. The dashed line represents a result when the preference
weights are observed for all study participants.
as well as uncertainty in the clinical data are taken into account using Markov Chain
Monte Carlo simulation. We believe that this approach could be useful if the preference
survey results are available prior to new NI trial initiation, and if both survey and NI
trial participants come from the same patient population. In order to evaluate a possi-
ble implication of the differences between survey and NI trial participants, we simulated
Scenario 3 from Section 5.2 assuming that survey participants are sicker than those in
NI trial. Specifically, we assumed that 70%, 20% and 10% of the survey participants
have low, medium and high BCVA BL values respectively, as well as 90% have high CST
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values. Since we anticipate patients’ preferences to be affected by BL characteristics,
encountering sicker patients will translate into higher BCVA and CST preferences. Us-
ing the mean values of the new preferences along with the outcome values of the study
participants in accordance with Broekhuizen et al. [2017], we received 42.8% of simu-
lated studies concluding favorable BR of the non-inferior treatment. This is 10% more
optimistic than the original 32.1%.
The above two comparisons underline the importance of taking into consideration
both outcome and preferences variability, as well as obtaining preferences from the same
patient population as being investigated during an NI study. While BR assessment is
critical for consideration of any new therapy, it is especially important for NI trials.
Given an acceptable clinical worsening in effectiveness of non-inferior treatment, there
is a need for formal assessment of the treatment’s advantages over a standard of care. If
the non-inferior treatment does not offer benefits that outweigh decreased effectiveness,
there is no justification for its approval. However, so far such formal BR assessment was
not used for non-inferior treatments. Hence, our novel approach provides a pragmatic
solution for BR assessment of non-inferior treatments.
The limitations of our study include the simulations that are limited to the scenarios
being considered in this Chapter. In addition, we used a partial linear function for
scoring of outcome criteria. The use of other function types is outside the scope of this
work.
The contribution of this Chapter is a development of a new tool for comprehensive
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BR assessment of non-inferior treatments. Since our approach is based on the data
collected during the study and therefore reported in the clinical study report, it would
facilitate a more transparent BR evaluation in practice. Moreover, incorporation of
the individual patients’ perspectives from the target patient population is aligned with
recent regulatory commitments to include patient preferences in BR assessment. Our
method contributes to a better decision making process with regards to new non-inferior
treatments.
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Chapter 6
Conclusion
This dissertation focuses on new approaches for the design and analysis of NI clinical
trials. Each Chapter presented in this dissertation looks at different statistical issues
related to this type of trial. Specifically, in Chapter 2, we provide a set of recommen-
dations for incomplete data analysis along with a novel approach for analysis of data
under MNAR. This contributes towards better analysis practices of NI trials. In Chap-
ter 3, we introduce MI combination rules for difference in binomial proportions, when
NW method is used. While we use this method for analysis of NI trials and therefore
contribute again towards better analysis of such trials, it is a general methodology which
is useful for other applications as well. In Chapter 4 we present a new framework for
incorporating different clinical experts opinions regarding NI margin into tthe design
and analysis of NI trials. While in Chapter 5, we develop a simple BR assessment ap-
proach for evaluation of overall benefit of non-inferior treatment. Both Chapter 4 and 5
advance design, analysis and interpretation of NI clinical trials. This dissertation pro-
vides an important contribution to the field of Statistics, and drug development. The
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novel methods and techniques outlined in this dissertation facilitate practitioners in-
volved with NI trails to make more efficient and transparent evaluations of treatment
effectiveness.
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Appendix A
A.1 Sample size per scenario and method
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Figure A1: Sample size per scenario and method
A.2 Outcome variable model
The baseline covariates were set to follow bivariate Normal distribution: (X1, X2) ∼
N2(µ1 = 4, µ2 = 100, σ1 = 1, σ2 = 20, ρ = −0.3), where µ1, µ2 represent mean values for
X1, X2 respectively, σ1, σ2 represent standard deviation values for X1, X2 respectively,
and ρ is a correlation coefficient between X1 and X2. X1 could for example represent
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disease status at baseline, while X2 could be a systolic blood pressure at baseline.
Model parameters in (8) were set as following: βGrpout = log
pTrt∗(1−pCon)
pCon∗(1−pTrt) , αy =
log pCon
(1−pCon) − β1out ∗ µ1 − β2out ∗ µ2, and β1out = 0.1, β2out = −0.01. The values of β1, β2
were found through simulation and were calibrated to achieve the target proportions of
favorable events in the treatment arms.
A.3 Additional results for Chapter 2
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Figure A2: Empirical power CCA imputation strategy for MCAR: drop-out rates are
balanced between the treatment groups
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Figure A3: Empirical power CCA strategy for MAR: drop-out rates are balanced be-
tween the treatment groups
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Figure A4: Empirical type-I error CCA strategy for MAR, overall drop-out rate of 20%
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Figure A5: Mean relative bias CCA strategy for MAR: drop-out rates are balanced
between the treatment groups
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Figure A6: Mean relative bias CCA strategy for MAR, overall drop-out rate of 20%
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Table A1: Mean relative bias for MNAR due to lack of efficacy in Trt for different
drop-out (DO) rates, CCA and two-stage MI strategies, Wald method
pCon DO M2 CCA MI
0.65 0.05 15% -0.697 -0.050
0.65 0.10 15% -0.351 -0.002
0.65 0.15 15% -0.230 0.008
0.75 0.05 15% -0.669 -0.056
0.75 0.10 15% -0.357 -0.014
0.75 0.15 15% -0.248 0.031
0.80 0.15 15% -0.257 0.002
0.85 0.05 15% -0.566 -0.082
0.85 0.10 15% -0.332 -0.011
0.65 0.05 10% -0.483 -0.052
0.65 0.10 10% -0.244 -0.013
0.65 0.15 10% -0.158 -0.001
0.75 0.05 10% -0.468 -0.058
0.75 0.10 10% -0.247 -0.019
0.75 0.15 10% -0.174 0.015
0.80 0.15 10% -0.181 -0.007
0.85 0.05 10% -0.399 -0.073
0.85 0.10 10% -0.233 -0.019
0.65 0.05 5% -0.258 -0.041
0.65 0.10 5% -0.130 -0.014
0.65 0.15 5% -0.088 -0.009
0.75 0.05 5% -0.248 -0.042
0.75 0.10 5% -0.129 -0.015
0.75 0.15 5% -0.095 -0.001
0.80 0.15 5% -0.099 -0.011
0.85 0.05 5% -0.210 -0.046
0.85 0.10 5% -0.122 -0.014
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Figure A7: Empirical power two-stage MI strategy for MNAR due to lack of efficacy in
Trt
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Figure A8: Empirical type-I errors, CCA strategy for MNAR due to overwhelming
efficacy in Con
118
l l
l
l l
l
l l
lll l l
l
l l
l
l
l l
l
l
l l
l
l l
ll l l ll
l
l l
ll ll
l
l
l l
l
l
l
l l
l
l
l l
ll ll l
l
l
l l ll l l l
l
l l
l
l l
l
l
l l
l
M2 : 0.15 pCon : 0.65 n : 212 aCon : N(1.85, 0.05) M2 : 0.15 pCon : 0.75 n : 175 aCon : N(1.55, 0.05) M2 : 0.15 pCon : 0.8 n : 149 aCon : N(1.55, 0.05)
M2 : 0.1 pCon : 0.65 n : 478 aCon : N(1.8, 0.05) M2 : 0.1 pCon : 0.75 n : 394 aCon : N(1.55, 0.05) M2 : 0.1 pCon : 0.85 n : 267 aCon : N(1.4, 0.05)
M2 : 0.05 pCon : 0.65 n : 1912 aCon : N(1.7, 0.05) M2 : 0.05 pCon : 0.75 n : 1576 aCon : N(1.45, 0.05) M2 : 0.05 pCon : 0.85 n : 1071 aCon : N(1.25, 0.05)
5% 10% 15% 20% 5% 10% 15% 20% 5% 10% 15% 20%
0.00
0.01
0.02
0.03
0.04
0.05
0.00
0.01
0.02
0.03
0.04
0.05
0.00
0.01
0.02
0.03
0.04
0.05
Drop−out rate (%)
Em
pi
ric
al
 T
yp
e−
I e
rro
r
Method l l lFM Wald WN
Figure A9: Empirical type-I errors, two-stage MI strategy via MICE for MNAR due to
overwhelming efficacy in Con
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Figure A10: Empirical power two-stage MI strategy for MNAR due to overwhelming
efficacy in Con
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Table A2: Mean relative bias for MNAR due to overwhelming efficacy in Con for different
drop-out (DO) rates, CCA and two-stage MI strategies, Wald method
pCon M2 DO CCA MI
0.65 0.05 20% -1.650 0.134
0.65 0.10 20% -0.831 0.093
0.65 0.15 20% -0.560 0.043
0.75 0.05 20% -1.185 0.098
0.75 0.10 20% -0.594 0.076
0.75 0.15 20% -0.406 0.017
0.80 0.15 20% -0.330 0.028
0.85 0.05 20% -0.689 0.050
0.85 0.10 20% -0.347 0.063
0.65 0.05 15% -1.235 0.147
0.65 0.10 15% -0.624 0.083
0.65 0.15 15% -0.421 0.040
0.75 0.05 15% -0.871 0.097
0.75 0.10 15% -0.437 0.065
0.75 0.15 15% -0.301 0.016
0.80 0.15 15% -0.244 0.020
0.85 0.05 15% -0.497 0.051
0.85 0.10 15% -0.250 0.047
0.65 0.05 10% -0.825 0.118
0.65 0.10 10% -0.418 0.060
0.65 0.15 10% -0.284 0.028
0.75 0.05 10% -0.569 0.077
0.75 0.10 10% -0.287 0.044
0.75 0.15 10% -0.201 0.010
0.80 0.15 10% -0.161 0.012
0.85 0.05 10% -0.318 0.041
0.85 0.10 10% -0.161 0.033
0.65 0.05 5% -0.419 0.059
0.65 0.10 5% -0.214 0.026
0.65 0.15 5% -0.149 0.009
0.75 0.05 5% -0.280 0.041
0.75 0.10 5% -0.142 0.021
0.75 0.15 5% -0.104 0.001
0.80 0.15 5% -0.084 0.001
0.85 0.05 5% -0.150 0.026
0.85 0.10 5% -0.077 0.017
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Figure B1: Coverage probability for MAR with independent X and Y (Dashed line
represents the desired coverage probability of .95, dotted line represents covarage probability
of .90.)
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Figure B2: Average width of 95% confidence intervals for MAR, with independent X
and Y
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Figure B3: Average width of 95% confidence intervals for MNAR
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Figure C1: Deviation from objective NI decision, when more experienced MDs are more
likely to participate in the survey, subject-level data are fully observed, ρ = 0.7.
Table C1: Percent of studies concluding NI by method, when more experienced MDs
are more likely to participate in the survey, subject-level data are MCAR, ρ = 0.7.
pTrt n OBJ MI OBS MIN MAX
0.775 250 22.8 19.4 10.3 78.7 1.1
0.775 500 39.1 32.9 15.0 97.4 0.9
0.800 250 48.8 41.2 25.6 92.4 4.7
0.800 500 77.9 68.7 42.0 99.8 6.2
0.825 250 77.2 69.1 49.5 98.7 15.1
0.825 500 96.9 92.7 74.7 100.0 26.6
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Figure C2: Deviation from objective NI decision, when MDs participation in the survey
is completely random, subject-level data are fully observed, ρ = 0.7.
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Figure C3: Deviation from population based non-inferiority decision, subject-level data
are MCAR, ρ = 0.7.
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Figure C4: Deviation from population based non-inferiority decision, subject-level data
are MAR, ρ = 0.7.
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